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Summary 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
triggers apoptosis in a variety of tumor cells, but not in normal cells. 
Therefore, TRAIL and in particular agonistic antibodies to the functional 
TRAIL receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) are currently being 
explored in pre-clinics and clinical trials for the treatment of various 
malignancies. 
TRAIL is highly prevalent in ovarian tumor microenvironment and is 
being associated with prolonged survival. In addition, more than two third of 
ovarian cancer (OC) patients have a disturbed TRAIL signaling pathway, a 
fact important not only for prognosis, but also for future therapeutic options. 
Defects in the TRAIL pathway include a downregulation of TRAIL functional 
receptors DR4 and DR5, and/or an overexpression of the long isoform of 
caspase-8 inhibitor protein cellular Fas-associated death domain-like 
interleukin-1β-converting enzyme (FLICE)-like inhibitory protein (c-FLIPL). 
 The central aim of my PhD thesis was to gain further insight into the 
deregulation of the TRAIL signaling axis as potential tumor escape 
mechanism in OC. In the first part of my PhD thesis I elucidated whether 
human OC resistance to TRAIL may be overcome by an agonistic anti-human 
DR5 monoclonal antibody (AD5-10). I identified that co-administration of AD5-
10 with carboplatin exhibits more than an additive effect in vitro, which may be 
explained by the finding that carboplatin upregulates DR5 expression on OC 
cells irrespective of the p53 status. The combination therapy of AD5-10 with 
carboplatin eliminated large established platin resistant ovarian tumors in vivo, 
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reducing tumor size to undetectable levels in more than 50% of mice 
(P=0.002). In addition, I found that TRAIL and natural killer (NK) cell 
expression are abundant in the tumor microenvironment, and that depletion of 
NK cells abolishes the antitumor activity of AD5-10. Taken together, these 
data show that a combination of agonistic anti-DR5 monoclonal antibody such 
as AD5-10 and carboplatin is a promising regimen for treatment of OC. These 
results also highlight the interplay between a therapy addressing the 
apoptosis cascade and the role of the immune system. 
In the second part of my PhD thesis I focused on the physiological role 
of c-FLIPL in OC progression. To address this question, a loss of function 
approach was applied utilizing RNA interference (RNAi) in OC in vitro and in 
vivo. I was able to demonstrate that suppression of c-FLIPL enhanced 
sensitivity of human OC cells to TRAIL-mediated apoptosis and significantly 
decreased tumor development in vivo. Interestingly, I observed that 
downregulation of c-FLIPL decreased the rate of apoptosis and proliferation in 
vivo. The knockdown of c-FLIPL particularly inhibited the invasion of OC cells 
into the peritoneal cavity, which might be due to the high expression of TRAIL 
by NK cells in the tumor-stroma. Altogether, these results indicate that c-FLIPL 
regulates TRAIL-induced apoptosis in OC cells. 
I complemented my work by utilizing an established syngeneic ovarian 
tumor model kindly provided by a collaboration partner, and obtained some 
very first insights into the interplay between the TRAIL pathway and OC in the 
immunocompetent situation. I observed that DR5 expression is reduced in all 
ten transformed mouse ovarian surface epithelial (MOSE) cell lines when 
compared to normal (non-tumorigenic) MOSE cells. About 70% of tumorigenic 
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MOSE cell lines were resistant to TRAIL-induced apoptosis. In a preliminary 
animal experiment, the downregulation of mouse DR5 accelerated the 
development of ascites and decreased mouse life span, which is in line with 
previous observations that TRAIL receptors play a key role in human OC.  
 In conclusion, the data generated in the course of my PhD thesis 
indicate that DR5 and c-FLIPL, in the context of the TRAIL signaling pathway, 
play a fundamental role in OC pathogenesis and thus are potential targets for 
future OC therapy.  
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Zusammenfassung 
TRAIL (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand) 
induziert in einer Vielzahl von Tumorzellen Apoptose, nicht jedoch in 
gesunden Zellen. Deshalb werden TRAIL selbst, sowie agonistische 
Antikörper für die funktionellen TRAIL-Rezeptoren (TRAIL-R1 (DR4) und 
TRAIL-R2 (DR5)) gegenwärtig in präklinischen und klinischen Studien für die 
Behandlung von diversen Erkrankungen untersucht. 
TRAIL ist im Mikroumfeld von Ovarialtumoren prävalent und wird mit 
verlängertem Überleben assoziiert. Mehr als zwei Drittel der 
Ovarialtumorpatientinnen haben einen gestörten TRAIL-Signalweg, ein 
wichtiges Faktum für Prognose und Therapiemöglichkeiten. Defekte im 
TRAIL-Signalweg beinhalten eine Reduzierung der funktionellen Rezeptoren 
DR4 und DR5 und/oder eine Überexpression der langen Isoform von c-FLIP 
(cellular Fas-associated death domain-like interleukin-1β-converting enzyme 
(FLICE)-like inhibitory protein, c-FLIPL). 
Das Hauptziel meiner Doktorarbeit war Einblicke in die Deregulierung 
des TRAIL-Signalweges als potentiellen Tumor-Escape-Mechanismus beim 
Ovarialkarzinom zu erhalten. Im ersten Teil meiner Arbeit habe ich untersucht, 
ob eine Resistenz gegen TRAIL beim Ovarialkarzinom durch einen 
agonistischen anti-humanen DR5 monoklonalen Antikörper (AD5-10) 
aufgehoben werden kann. Ich konnte zeigen, dass die gemeinsame 
Anwendung von AD5-10 mit Carboplatin einen mehr als additiven Effekt in 
vitro hat. Dies könnte dadurch erklärt werden, dass Carboplatin die DR5-
Expression an Ovarialkarzinomzellen, unabhängig von deren p53-Status, 
 7 
steigert. Eine Kombinationstherapie von AD5-10 mit Carboplatin eliminiert 
etablierte, platinresistente Ovarialtumore in vivo und reduziert deren Größe in 
mehr als 50 % der Mäuse (P=0.002) bis unter die Nachweisgrenze. Zusätzlich 
konnte ich zeigen, dass TRAIL und Natürliche Killerzellen (NK-Zellen) im 
Tumor-Mikroumfeld in sehr hohem Ausmaß vorhanden sind und der Abbau 
von NK-Zellen die antitumorale Aktivität von AD5-10 aufhebt. 
Zusammengefasst zeigen diese Daten, dass eine Kombination eines 
agonistischen monoklonalen anti-DR5 Antikörpers wie AD5-10 und 
Carboplatin eine vielversprechende Therapie für die Behandlung des 
Ovarialkarzinoms sein kann. Diese Ergebnisse zeigen auch die Interaktion 
zwischen einer Therapie, die die Apoptose-Kaskade in Gang setzt, und der 
Rolle des Immunsystems. 
Im zweiten Teil meiner Arbeit habe ich mein Hauptaugenmerk auf die 
physiologische Rolle von c-FLIPL in der Ovarialkarzinomentstehung gelegt. 
Um auf diese Frage einzugehen, habe ich die Loss-of-Function-Methode, 
unter Verwendung von RNA Interferenz (RNAi) im Ovarialkarzinom in vitro 
und in vivo, angewendet. Es war mir möglich zu zeigen, dass durch die 
Unterdrückung von c-FLIPL die Sensitivität von menschlichen 
Ovarialkarzinomzellen für TRAIL-induzierte Apoptose erhöht und die 
Tumorentstehung in vivo gehemmt wird. Von besonderem Interesse war die 
Beobachtung, dass eine Reduzierung von c-FLIPL die Apoptoserate und die 
Proliferation in vivo senkt. Die Reduzierung von c-FLIPL verhinderte 
insbesondere die Invasion der Ovarialkarzinomzellen in die Peritonealhöhle, 
eine Beobachtung die auf die hohe Expression von TRAIL durch die NK-
Zellen im Tumorstroma zurückzuführen sein könnte. Alles in allem zeigen 
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diese Resultate, dass c-FLIPL die TRAIL-induzierte Apoptose in 
Ovarialkarzinomzellen wesentlich beeinflusst. 
Ich habe meine Arbeit durch die Verwendung eines etablierten, 
immunkompetenten Ovarialtumor-Modells ergänzt, welches freundlicherweise 
von einem Kooperationspartner zur Verfügung gestellt wurde. Durch die 
Anwendung dieses Modells erhielt ich allererste Einsichten in die Interaktion 
zwischen dem TRAIL-Signalweg und dem Ovarialkarzinom in einer 
immunkompetenten Situation. Ich konnte beobachten, dass DR5 in allen zehn 
tumorigenen MOSE (Mouse-Ovarial-Surface-Epithel)-Zelllinien weniger 
exprimiert wird als in normalen (nicht-tumorigenen) MOSE-Zellen. Rund 70 % 
der tumorigenen MOSE-Zelllinien waren resistent gegen TRAIL-induzierte 
Apoptose. In einem vorangegangenen Tierexperiment hat die Reduktion von 
Maus-DR5 die Entstehung von Aszites beschleunigt und die Lebensspanne 
der Mäuse verkürzt. Dies stimmt mit unseren früheren Beobachtungen, 
bezüglich der zentralen Rolle von TRAIL-Rezeptoren im menschlichen 
Ovarialkarzinom, überein. 
Zusammenfassend zeigen die Ergebnisse meiner Dissertation, dass 
DR5 und c-FLIPL im Zusammenhang mit dem TRAIL-Signalweg eine 
fundamentale Rolle in der Pathogenese des Ovarialkarzinoms spielen und 
dass DR5 und c-FLIPL potentielle Ziele für die Therapie des Ovarialkarzinoms 
darstellen. 
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1. Introduction 
1.1. Ovarian Cancer 
Ovarian cancer (OC) is the most lethal gynecological malignancy and the fifth 
leading cause of cancer-related deaths among women (1, 2). OC originating 
from the ovarian surface epithelium (OSE) is the most common form and is 
displayed in a range of histological subtypes. The OSE consists of a single 
layer of squamous to cuboid cells covering the surface of the ovary and arises 
ontogenetically from the mesothelial lining of the embryonic coelom. It shares 
many common histological features with the rest of the peritoneum, albeit 
being phenotypically different and developmentally less mature than the 
peritoneum itself (3). Generally accepted risk factors for OC include genetic 
predispositions based on germline mutations in DNA repair genes (BRCA1, 
BRCA2, HNPCC), and hormonal and lifestyle factors such as early menarche, 
late menopause and number of pregnancies. Most of these risk factors 
influence the number and quality of the repeated trauma to the OSE during 
ovulation (incessant ovulation theory (4)) and in parallel paracrine hormonal 
exposure from ovarian stroma. Surface papilations, invaginations and 
inclusion cysts of OSE, which may develop in an ovulating ovary, are 
therefore thought to be putative premalignant lesions due to their increased 
incidence in high-risk populations. 
 
1.2. TRAIL and its receptors 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also 
designated as Apo2L, is a type II transmembrane protein of about 33-35 kDa 
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(5). TRAIL was identified by homology search of a highly conserved sequence 
motif characteristic for the TNF family members (6, 7). Like Fas ligand (FasL) 
and TNF-α, TRAIL can be cleaved from the membrane by metalloproteases, 
and the resulting soluble TRAIL has been shown to maintain biological 
activity. The extracellular domain of TRAIL forms a bell-shaped homotrimer, 
like other ligands of the TNF family (8, 9), by a cysteine residue at position 
230 that coordinates with divalent zinc. Human TRAIL has been proven to 
bind to five different paralogous receptors; TRAIL-R1/DR4, TRAIL-R2/DR5, 
TRAIL-R3/DcR1, TRAIL-R4/DcR2 and osteoprotegrin (10). While DR4 and 
DR5 are intact functional TRAIL receptors, the others do not contain a 
functional death domain and may thus act as decoy receptors competing with 
DR4 and DR5 for TRAIL (Fig. 1.1) (11). Interestingly, the genes for the DR4, 
DR5, DcR1, and DcR2 receptors are tightly clustered on human chromosme 
8p21-22 (12-14). Osteoprotegrin (OPG) is a soluble receptor stimulating 
osteoclastogenesis by competing with receptor activator of NF-KB (RANK) for 
RANK ligand. It has however been shown to bind TRAIL with only a very low 
affinity (15). 
Interestingly, in mice it has been shown that there is only one death-
inducing receptor homologous to human DR5 (mTRAIL-R2/mDR5), and two 
potential decoy receptors (mDcTRAIL-R1/mDcR1 and mDcTRAIL-R2/mDcR2) 
specific for mouse TRAIL (Fig. 1.1) (16). Mouse DR5 (mDR5) contains the 
death domain and signals apoptosis in response to both mouse and human 
TRAIL. mDcR1 is a GPI-anchored membrane protein that binds mouse, but 
not human TRAIL. mDcR2 can be expressed as two alternative splicing 
variants, a secreted form (mDcR2S) and a transmembrane form (mDcR2L), 
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which binds with both mouse and human TRAIL. OPG can also bind to mouse 
TRAIL, and may act as soluble decoy receptor for TRAIL. 
In humans, DR4 and DR5 receptors are characterized by an 
extracellular cystein-rich domain and an intracellular death domain giving 
them the ability to trigger the assembly of the death-inducing signaling 
complex (DISC) upon ligand stimulation which initiates the apoptotic cascade. 
The cytoplasmic regions of both DR4 and DR5 contain a death domain 
homologous to Fas and TNF-R1. Recent studies have shown that DR5, and 
less clearly DR4, signal apoptosis in a similar way to Fas (17). Mutations in 
DR5 encoding gene have been described in several cancers like in head and 
neck cancer (18), non small cell lung (19), breast cancer (20), colorectal 
cancer (21), gastric cancer, and hepatocellualr carcinoma (22). 
 
 
 
 
 
 
Figure 1.1. TRAIL receptors in 
human and mouse (adapted from 
(23)). TRAIL binds to two functional 
receptors, DR4 and DR5, in human, 
and one functional receptor in mouse, 
mDR5. Functional receptors encode 
intact death domain and can therefore 
transmit signals, which may result in 
induction of apoptosis. Also, TRAIL 
can bind with DcR1, DcR2 and OPG 
in both species (mDcR1 and mDcR2 
in mouse), which lack functional death 
domain and therefore act as decoy 
receptors. 
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1.3. TRAIL signaling pathway 
Trimerization of DR4 and DR5 by TRAIL on the surface of target cells leads to 
recruitment of adaptor molecule Fas-associated death domain protein 
(FADD), which in turn leads to recruitment and activation of caspase-8 (24). In 
certain cell types, type I (type I proteins are characterized by having their 
amino terminus side exposed on the exterior side of the membrane and the 
carboxy terminus exposed on the cytoplasmic side), activation of caspase-8 is 
sufficient for subsequent activation of the effector caspase-3 to execute 
cellular apoptosis (extrinsic pathway, Fig. 1.2) (25). In other cell types, type II 
(type II membrane proteins are characterized by having their amino terminus 
exposed on the cytoplasmic side of the cell and the carboxy terminus exposed 
on the exterior), amplification occurs through the mitochondrial pathway 
(intrinsic pathway, Fig. 1.2), which is initiated by cleavage of Bid by caspase-8 
(25). The truncated Bid (tBid) translocates to the mitochondria and leads to 
Bax and Bak-mediated release of cytochrome-c (cyt-c) and Smac/DIABLO 
from mitochondria. The released cyt-c binds to Apaf-1 to activate caspase-9, 
which in turn activates caspase-3. The Smac/DIABLO promotes caspase-3 
activation by preventing IAPs from attenuating caspases. Activation of 
extrinsic and intrinsic pathways by TRAIL depends on the cellular context. As 
a potential resistance mechanism, in contrast to DR4 and DR5, DcR1 is a 
GPI-anchored membrane protein and does not mediate apoptosis; DcR2 
contains a truncated death domain, which also does not mediate apoptosis. 
Hence, DcR1 and DcR2 may act as decoy receptors, which compete with 
DR4 and DR5 for TRAIL binding. Cellular Fas-associated death domain-like 
interleukin-1β-converting enzyme (FLICE)-like inhibitory protein (c-FLIP) can 
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prevent the recruitment of caspase-8. Bcl-2 and Bcl-xL can suppress the 
Bax/Bak-mediated release of cyt-c and Smac/DIABLO from mitochondria. 
IAPs can attenuate the activities of caspase-9 and caspase-3, although 
Smac/DIABLO can counteract IAPs (Fig. 1.2) (23). The cytoplasmic regions of 
DR5 and DcR2 contain potential TRAF-binding motifs, which may be 
responsible for NF-kB and MAP kinase activation by these receptors (23). 
 
Figure 1.2. Schematic overview illustrating the TRAIL-induced apoptosis 
signaling pathway. Upon ligation of TRAIL ligand to its respective receptors DR4 
and DR5, FADD protein is recruited, which in turn leads to recruitment and activation 
of caspase-8. Activation of caspase-8 leads to either activation of cell- extrinsic 
(mitochondria independent) or cell-intrinsic (mitochondria dependent) pathway. Both 
pathways lead to activation of active caspases such as caspase 3, which cause 
chromatin condensation and apoptosis. 
 
1.4. c-FLIP as inhibitor of TRAIL functional receptors-
mediated apoptosis 
c-FLIP was initially identified in 1997 in various γ-herpesviruses and poxvirus 
MCV (26-28). Viral FLICE inhibitory proteins (v-FLIP) were named so as they 
displayed inhibitory effects on apoptosis through caspase-8 inhibition. In 1997 
human cellular-FLIP (c-FLIP) was identified, also named FLAME-1, I-FLICE, 
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Casper, CASH, MRIT, CLARP, and usurpin, which is located on chromosome 
2q33-34 (29-36). While there are 13 distinct splice variants of c-FLIP mRNA 
(37), three splice variants were detected at the protein level: c-FLIPL, c-FLIPs 
and c-FLIPR (38).  
Both c-FLIPL and c-FLIPs have been shown to interact with FADD and 
procaspase-8 and consequently, inhibit apoptosis induced by death receptors 
like FAS, DR4 and DR5 (Fig. 1.3 and Fig. 1.4) (29-31, 33-36). Although, c-
FLIP proteins (c-FLIPS and c-FLIPL) are recruited to the DISC, they do not 
preclude capsase-8 from recruitment to the DISC (39). c-FLIPL is cleaved into 
two subunits  p43 and p12 subunits, p43 subunit remains at the DISC and p12 
subunit releases (Fig. 1.4A) (39). In the presence of large amount c-FLIPL, 
caspase-8 is incompletely cleaved upon recruitment to the DISC (Fig. 1.4.C) 
(39, 40). However, in presence of large amount of c-FLIPs, processing of 
capsase-8 is completely prevented at the DISC (Fig. 1.4.D) (40). 
 
 
Figure 1.3. Diagram showing structural similarities between caspase-8 and c-
FLIP proteins [adapted from (41)]. c-FLIPL encoded tandem death effector domains 
(DEDs) and caspase like domain; however, it lacks amino acid residues that are 
required for caspase activity. c-FLIPs and v-FLIP are similar consisting of two DEDs 
and a short c-terminal part. 
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Figure 1.4. Model showing mechanism of action of c-FLIP at the DISC [adapted 
from (41)]. A) CD95L binds with CD95 and induces formation of the DISC. B-D) The 
ratio of procaspe-8 and c-FLIP proteins at the DISC controls cleavage and activation 
of caspase-8. B) In presence of small amount of c-FLIP, procaspase-8 is cleaved, 
producing active caspase-8 heterotetramer composed of the p18 and p10 subunits. 
C) In the presence of high amount of c-FLIPL, procaspase-8 is cleaved upon 
recruitment to the DISC; however, its cleavage is incomplete. D) In the presence of a 
large amount of c-FLIPs recruitment of procaspase-8 at the DISC occurs; however, 
procaspase-8 remains unprocessed. 
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1.5. TRAIL and immunosurveillance 
Natural killer (NK) cells and cytotoxic T lymphocytes both have the ability to 
destroy tumor cells by various mechanisms, one of them being the production 
of death ligands such as FasL or TRAIL. While TRAIL mRNA is constitutively 
expressed in a wide variety of normal tissues, the expression of functional 
TRAIL protein appears to be rather restricted to immune cells (42-48). In 
addition, TRAIL-deficient mice do not show large abnormalities, except for 
impaired tumor immunosurveillance and higher sensitivity to experimental 
autoimmune diseases, such as collagen-induced arthritis (CIA), 
streptozotocin-induced diabetes, and experimental autoimmune 
encephalomyelitis (EAE). These facts support the hypothesis of the 
physiological role of TRAIL in the immune system (23, 49-51). 
 TRAIL is involved in the cytotoxic activity of activated NK cells directed 
against tumor cells in vitro (52), and is at least in part responsible for their 
antimetastatic activities in vivo (53, 54). The physiological regulation of NK 
cell activity is largely dependent on expression of MHC class I molecules. In 
normal cells, NK cells receive inhibitory stimulation from MHC class I 
molecules on the surface of their respective target cells. Nevertheless, 
expression of stimulatory molecules, such as CD27 or CD28, was also found 
in NK cells. These receptors may activate NK cell function upon interaction 
with their specific ligands, CD70 or CD80/CD86 respectively, which are found 
to be expressed in a variety of tumors (55). TRAIL has been shown to play a 
critical role in interferon (IFN)-γ-dependent NK cell protection from tumor 
metastasis (56, 57). Malignant transformation of cells may result in expression 
of some ligand for NK cell-activating receptor (NKR) and/or downregulation of 
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MHC class I (MHC-I) molecules engaging NK cell inhibiting receptor (KIR), 
thereby activating NK cells. The activated NK cells produce IFN-γ, which in 
turn up-regulates TRAIL expression on NK cells and sensitizes transformed 
cells to TRAIL, resulting in tumor suppression (Fig. 1.5). 
 Furthermore, IFN-producing killer dendritic cells (IKDCs) mediate lysis 
of tumor cells, which are poorly recognized by NK cells, by secreting high 
levels of IFN-γ followed by TRAIL dependent apoptosis (58). A number of 
recent studies using neutralizing antibodies to TRAIL, or TRAIL-/- mice, 
showed that TRAIL could limit the development of experimental tumors (52, 
54). In these mouse tumor models, liver NK cells were the important source 
of TRAIL, and were responsible for protection against liver metastasis of 
TRAIL-sensitive tumors (49, 52, 54, 59). The in vivo effect of IL-12 or α -
galactosylceramide (α-GalCer) appeared to be due, at least, to an increase 
in the level of IFN-γ and TRAIL in these mice following the biological 
therapies (57, 60). A role for TRAIL in host immunosurveillance against 
primary tumor development has also been described (49, 52, 61). All these 
findings provide support for the physiological function of TRAIL as a tumor 
surveillance factor. 
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Figure 1.5. The model indicates the role of TRAIL in immunosurveillance 
hindering tumor development. Natural killer cell activating receptors (NKR) 
recognize ligands on tumor cells and activate protein tyrosine kinase (PTK), whose 
activity is inhibited by killer inhibitory receptors (KIR) that recognize MHC class I 
antigens and activate protein tyrosine phosphatases (PTP). The activated NK cells 
produce IFN-γ, which subsequently activates expression of TRAIL on activated NK 
cells. As a result, activated NK cells eliminate the transformed cells in a TRAIL-
dependent manner. 
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2. Aim of my PhD thesis 
The overall aim of my PhD study was to decipher the key role of the TRAIL 
signaling pathway in terms of DR5 and c-FLIPL in inhibiting OC development. 
Moreover, I also aimed to shed some light on the mechanisms by which OC 
cells escape the natural immunosurveillance and subsequently acquire the 
potential to develop overt malignancy.  
In the course of my PhD thesis I used two different animal models that 
made it possible to investigate different aspects of TRAIL-mediated 
cytotoxicity in protecting the host from ovarian tumor formation in vivo:  
The xenograft mouse model reflects similarities with human OC but 
tumorigenesis can only be studied in immune deficient animals providing a 
strategy to model late stages of OC progression. I prepared and inoculated 
parental and genetically modified human OC cells in nude mice which lack T 
cell lympocytes and therefore prevent xenograft rejection of the introduced 
tumors. This model offered an ideal environment to perform in vivo functional 
analysis of the role of DR5 and c-FLIPL in human ovarian tumor development, 
which is not possible in an immunocompetent mouse model. 
 The syngeneic mouse model naturally displays species differences 
with human cancer, but tumorigenesis can be studied in an immunocompetent 
setting, which reflects both early and late stages of the disease. I applied this 
model in pathogen-free C57BL/6 mice. 
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To provide a clear layout of my PhD thesis, two specific aims were 
defined: 
Specific Aim-I. Functional analysis of TRAIL signaling pathway in OC 
progression. In particular, my aim was to describe the molecular basis of DR5 
and c-FLIPL on the outgrowth of ovarian tumor in vitro and in vivo. Moreover, I 
also aimed to study the role of NK-mediated tumor immunity against OC.  
Specific Aim-II. Characterisation of the TRAIL pathway in a syngeneic mouse 
model of OC. Specifically, I aimed to analyze the expression of mDR5, c-
FLIP, and caspase-8 in ten established transformed mouse ovarian surface 
epithelial (MOSE) cell lines and to compare their expression to normal (non-
tumorigenic) MOSE cells, as well as to measure their sensitivity to TRAIL-
induced apoptosis. Furthermore, I aimed to apply loss of function approach to 
analyze the influence of DR5 on the development of OC in immunocompetent 
mice. 
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Abstract 
The TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis 
specifically in cancer cells with little effect on normal cells. We have previously 
demonstrated that TRAIL signaling is altered in most ovarian cancer (OC) 
patients, and that resistance to TRAIL contributes to OC progression. In this 
study we investigated whether resistance to TRAIL may be overcome by a 
monoclonal TRAILR2 (DR5) agonistic antibody (AD5-10). We found that the 
joint presence of AD5-10 with TRAIL and NK-cells expressed TRAIL 
resensitizes OC cells to apoptosis in vitro and in vivo respectively. The 
combination of AD5-10 with carboplatin exerts a more than additive effect in 
vitro, which may at least partially be explained by the fact that carboplatin 
triggers DR5 expression on OC cells. Moreover, AD5-10 restores the 
sensitivity of platin-resistant OC to carboplatin in vivo. In addition, we found 
that TRAIL expression and natural killer (NK) cells are abundant in the tumor 
microenvironment, and that depletion of NK cells abolishes the antitumor 
activity of AD5-10. This indicates that NK-mediated immunosurveillance 
against OC might be mediated by TRAIL and that apoptosis-induced by AD5-
10 requires the presence of NK cells. In conclusion, this study indicates a key 
role and strong antitumorigenic effect of DR5, and highlights a novel link 
between NK-mediated immunosurveillance and activation of DR5-mediated 
apoptosis in OC. 
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Introduction 
Ovarian cancer (OC) is the most lethal gynaecological cancer and the fifth 
leading cause of cancer-related deaths among women in western 
industrialized countries (1, 2). OC originating from the ovarian surface 
epithelium (OSE) is the most common form and displays a range of 
histological subtypes (3). While most OCs are sensitive to platin-based 
chemotherapy at the time of diagnosis, recurrence of the disease is frequent, 
and ultimately platin-resistant disease develops in all patients. 
 Apoptosis is important for maintaining cellular homeostasis in normal 
tissues by eliminating disordered cells, and defects in the apoptosis pathway 
may lead to cancer (4). The apoptotic cascade can be stimulated by death 
receptors, resulting in activation of caspases (5). Trimerization of TRAIL 
(tumor necrosis factor related apoptosis-inducing ligand) functional receptors 
TRAILR1 (DR4) or TRAILR2 (DR5) by their ligands leads to assembly of the 
death-inducing signaling complex (DISC), which initiates the apoptotic 
cascade (6). DR4 and DR5 are characterized by an extracellular cystein-rich 
domain and an intracellular death domain, giving them the ability to trigger the 
assembly of the DISC. We have previously found that TRAIL is highly 
expressed in the human OC microenvironment, but that tumor tissues display 
a reduced number of TRAIL functional receptors (7). 
 One major physiological role of TRAIL is the mediation of natural 
immunity and the elimination of developing tumors (8, 9). Previous studies 
have shown that soluble TRAIL, or agonistic monoclonal antibodies specific 
for functional TRAIL receptors, exhibit tumoricidal activities, a phenomenon 
that has been tested in clinical trials (10). The agonistic human DR5 specific 
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monoclonal antibody AD5-10 used in this study was reported to mediate 
antitumor effects in various tumor cells and due to its unique binding site does 
not compete with TRAIL for binding to DR5 in contrast to other agonistic DR5 
antibodies (11). 
 In the current study, we identified the functional role of DR5 in OC 
progression, and shed light on a novel strategy to eliminate OC in a preclinical 
mouse model. Moreover, we show for the first time that the function of NK 
cells is necessary for the activation of DR5-mediated apoptosis and that the 
presence of NK cells is highly correlated with a longer life span in xenograft 
mice. 
 
Results and Discussion 
   34 
Material and methods 
Drugs 
Carboplatin, paclitaxel (both EBEWE), bevacizumab (Roche), lapatinib 
(GlaxoSmithKline), agonistic DR5 monoclonal antibody (AD5-10) prepared as 
described previously (11), and recombinant human soluble TRAIL (Alexis) 
were used for stimulation of OC cell lines at various concentrations.  
 
Cell culture 
The human OC cell lines MDAH-2774 (ovarian endometroid adenocarcinoma 
(OEA)-derived cell line, originating from ascitic fluid of a patient (12)), and a 
platin resistant sub-line of the OC cell line A2780 (human epithelial OC cell 
line established from tumor tissue (13)) were cultured in RPMI 1640 medium 
(Invitrogen). The OC cell line ES-2 (human ovarian clear cell carcinoma cell 
line taken from a 47-year-old woman (14)) was cultured in McCoy’s medium 
(Invitrogen). Medium was supplemented with 10% FCS (PAA Laboratories 
GmbH), 1 mmol/L glutamine, and 1% penicillin/streptomycin (PAA 
Laboratories GmbH). MDAH-2774 and ES-2 cell lines were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA), and the cell line 
A2780 was obtained from the European Collection of Cell Cultures (ECACC, 
Salisbury, Wiltshire, UK). 
 
Determination of apoptosis 
MDAH-2774, A2780, and ES-2 OC cell lines were plated at a density of 5 x 
104 cells/well in 24-well plates and incubated for 24 h prior to stimulation. 
Then cells were treated with either AD5-10 (1 µg/ml) or carboplatin (100 
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µg/ml), paclitaxel (0.05 µM), bevacizumab (100 ng/ml), lapatinib (4 µM) or with 
an antibody–drug combination for 24 h. Cells were harvested by trypsinization 
using 0.05% trypsin and 0.02% EDTA without Ca2+ and Mg2+ (PAA 
Laboratories GmbH). Apoptosis was determined by an annexin V-FITC 
apoptosis detection kit (Alexis) according to the manufacturer’s instructions. 
Flow cytometry of annexin V-FITC and Pidium Iodide (PI) staining was 
performed using FACScan (Becton Dickinson) with CELLQuest Pro software. 
 
Immunoblotting analysis 
Western blot analysis was performed according to the standard protocol. 
Briefly, proteins were extracted from cells lysed for 30 min at 4oC in RIPA+ 
buffer supplemented with complete protease inhibitor (Roche) and 1 mM 
orthovanadat, followed by high speed centrifugation. Protein concentration 
was determined according to the method of Bradford (Sigma-Aldrich). Equal 
amounts of protein (~ 50 µg protein per lane) were separated by 12% SDS-
PAGE gel and electroblotted onto PVDF membranes (GE Healthcare). The 
membrane proteins were incubated with the following primary antibodies: 
mouse anti-caspase-8 monoclonal antibody, 12F5 (recognizes human 
procaspase-8 and active human caspase-8, Alexis), mouse anti-caspase-3 
monoclonal antibody, 31A1067 (recognizes human procaspase-3 and active 
human caspase-3, Imgenex), mouse anti-p53 monoclonal antibody (Cell 
Signaling), and goat anti-actin polyclonal antibody (Santa Cruz). Detection 
was performed with the appropriate peroxidase-conjugated (HRP) secondary 
antibody (Santa Cruz). The membranes were developed using enhanced 
chemoluminescence (ECL, Amersham). 
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Detection of TRAIL ligand and its functional receptor expression by flow 
cytometry 
MDAH-2774, A2780, and ES-2 OC cell lines were collected and washed in 
PBS. The cells were then incubated with mouse monoclonal antibodies 
against human TRAILR1, HS101 (Alexis), human TRAILR2, HS201 (Alexis), 
or mouse IgG1 isotype control (Ancell) for 1 h at 4oC. Afterwards, cells were 
washed in PBS, incubated with goat anti-mouse IgG-FITC (Santa Cruz) for 1 
h at 4oC in the dark and washed with PBS and analysed by flow cytometry. 
TRAIL intracellular staining was performed as described previously (15). 
Briefly, cells were washed with PBS and resuspended in 2% formaldehyde 
and incubated for 10 min at 4oC. Afterwards, cells were washed with PBS and 
resuspended in blocking solution (0.1% Saponin and 20% serum) and 
incubated for 20 min at room temperature.  Cells were then stained with 
mouse monoclonal antibody against human TRAIL, III6F (Alexis) or mouse 
IgG2b isotype control (Ancell) for 30 min at room temperature in staining 
buffer (0.1% Saponin, 2% FCS serum). After that, cells were washed three 
times with staining buffer, resuspended in secondary antibody goat anti-
mouse IgG-FITC (Santa Cruz), and incubated for 1 h at 4oC in staining buffer. 
Then, cells were washed three times with staining buffer and analysed by flow 
cytometry. Flow cytometric analysis was performed using FACScan (Becton 
Dickinson) and the resulting data were analysed with CELLQuest Pro 
software. 
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Immunohistochemistry 
Immunohistochemical analysis was performed using paraffin embedded 
sections as described previously (7). Briefly, tissue sections were 
deparaffinized and rehydrated. For epitope retrieval, specimens were 
incubated in 96°C pre-warmed 10 mM citrate buffer (pH 6.0) for 20 min. 
Slides were then incubated with 0.3% H2O2/PBS for 10 min at room 
temperature to block endogenous peroxidase. After blocking the background 
staining with serum of the secondary antibody (diluted 1:10 in PBS), tissues 
were incubated for 1 h at room temperature with primary antibody diluted in 
serum/PBS. The following primary antibodies were used: rabbit anti-human 
cleaved caspase-3 monoclonal antibody, Asp175 (dilution 1:50, Cell 
Signaling); mouse anti-human Ki-67 monoclonal antibody (dilution 1:200, 
Dako); goat anti-mouse TRAIL polyclonal antibody, AF1121 (dilution 1:100, 
R&D Systems); rabbit anti-human TRAILR1 polyclonal antibody, H130, 
(dilution 1:200, Santa Cruz); rat anti-mouse Ly-49G2 monoclonal antibody, 
4D11 (16) (dilution 1:400, eBioscience). The appropriate secondary 
biotinylated antibodies (Vector Laboratories) were diluted with the 
serum/PBS-buffer (dilution 1:200) and incubated for 30 min at room 
temperature. Tissue sections were incubated with StreptABComplex/HRP 
(Dako) for 45 min at room temperature and then visualized with DAB (Dako) 
and counterstained with Mayer’s Haematoxyline. Tissue sections were 
analysed on an Olympus BX50 upright light microscope (Olympus Europe) 
equipped with the Soft Imaging system CC12. 
Apoptosis was measured by using an in situ cell death detection kit 
(Roche) according to the manufacturer’s instructions. Afterwards the cells 
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were analysed on a fluorescence microscope (Nikon Eclipse 800) equipped 
with a Nikon DS-R1 camera, using the NIS-Elements software.  
Negative controls were performed by excluding incubation with primary 
antibody, and yielded negative results. The percentage of positive cells was 
determined by a blinded operator. 
 
Xenograft mouse model 
Four to six week-old female athymic nude-Foxn1 nu/nu mice were obtained 
from Harlan (Italy) and maintained under specific pathogen-free conditions at 
the animal resource service of the Medical University of Vienna. Mice were 
subcutaneously inoculated with A2780 OC cells on both sides. Treatment 
started on day 2 by intraperitoneal injection of PBS, AD5-10, carboplatin, or 
the latter two in combination. Tumor size was measured every second day by 
calipers. The tumor volume was calculated according to the formula V=4/3 x π 
x (L/2 x W/2 x W/2); L, length; W, width (17). At the end of the experiment, 
tumors were recovered and weighed and then prepared for histological and 
pathological analysis. Animal experiments were performed according to 
protocols approved by the Austrian Federal Ministry for Education, Science 
and Art. For NK depletion experiments, mice were treated with 20 µl anti-
asialo GM1 antibody (Wako) and 100 µ g NK1.1 antibody (prepared as 
described previously (18)) 3 days before inoculation, and then every 4 days.  
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Generation of splenocytes and analysis of NK cells 
The spleen was removed from sacrificed mice and placed into 60 mm tissue 
culture dishes. A single cell suspension was made by passing the tissue 
through a 70 µm nylon cell strainer (BD Bioscience) in PBS containing 2% 
FCS. Cells were centrifuged and hypotonic lysis of red blood cells was 
performed using ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM 
Na2EDTA, pH 7.2), followed by resuspension in an appropriate volume of 
PBS containing 2% FCS. Cells were incubated at 4oC with Fc-block (BD 
Bioscience) for 5 min, and then stained with PerCP Hamster anti-mouse 
CD3e, APC mouse anti-mouse NK-1.1, and FITC rat anti-mouse CD49b (BD 
Bioscience) antibodies for 30 min at 4oC in PBS. After that, cells were washed 
three times with PBS and analysed by flow cytometry. Flow cytometric 
analysis was performed on FACSCalibur (BD Biosciences). Data were 
analysed using the CellQuest Pro software. 
 
Statistical analysis 
Two-sided Student’s t-tests were used to detect statistically significant 
differences between study groups and controls, using R and Statstoft’s 
Statistica software. Data were visualized with box plots or bar plots. P values 
below 0.05 were considered statistically significant, and P values below 0.005 
were considered highly significant. The correlation between variables was 
estimated using the Pearson correlation coefficient. 
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Results  
In vitro effect of combining AD5-10 with cytotoxic drugs  
We have previously demonstrated that the TRAIL signaling pathway plays a 
fundamental role in OC progression (7, 19). In this study, we addressed the 
functional role of human DR5 using three distinct OC cell lines (MDAH-2774, 
A2780, ES-2). The selected OC cell lines have accumulated different 
mutational and epigenetic changes that alter normal cell growth and survival 
pathway e.g. mutated p53 in MDAH-2774 and ES-2, epigenetic silencing of 
DR4 in A2780, as well as upregulation of c-FLIP in most of them (19-22).  
Moreover, they express different levels of DR5 (Fig. 3.1.1A) and all of them 
were resistant to TRAIL-induced apoptosis. We found that AD5-10 triggered 
tumor cell apoptosis to a detectable extent and had an additive effect when 
combined with different pharmacological and cellular anticancer agents 
(paclitaxel, bevacizumab, and lapatinib; Fig. 3.1.1B). In combination with 
carboplatin, AD5-10 showed a more than additive effect (Fig. 3.1.1B), 
illustrated by comparing the sum effect of AD5-10 and carboplatin to a 
combination of both. This particular effect was observed in three different 
carboplatin-resistant OC cell lines and was confirmed by detection of active 
caspase cleavage fragments (Fig. 3.1.1B and C). The dose response curves 
for carboplatin in the presence of AD5-10 confirmed the observed effects (Fig. 
3.1.1D). Together, these findings suggest that AD5-10-mediated stimulation of 
DR5 in the presence of carboplatin efficiently sensitizes OC cell lines to 
apoptosis. 
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Figure 3.1.1. Effect of combining AD5-10 with carboplatin in vitro. A) Histogram 
showing expression of the TRAIL ligand as well as its functional receptors DR4 and 
DR5 on the surface of selected OC cell lines as determined by flow cytometry. 
Selected OC cell lines were stained with either TRAIL ligand (III6F, Alexis), anti-DR4 
(HS101, Alexis), anti-DR5 (HS201, Alexis) monoclonal antibody (coloured 
histogram), or isotype control IgG1 monoclonal antibody (unfilled histogram). Data 
represent three independent experiments. B) Upper panel, the A2780 OC cell line 
was treated with either AD5-10 (1 µg/ml), carboplatin (100 µg/ml), paclitaxel (0.05 
µM), bevacizumab (100 ng/ml), lapatinib (4 µM) or with an antibody-drug combination 
for 24 h. Apoptosis was determined by annexin-V and PI staining. Numbers in dot 
plot quadrants represent the percentage of stained apoptotic cells. Lower panel, 
quantitative evaluation of upper panel as well as the apoptosis rate of MDAH-2774 
and ES-2 OC cell lines. Columns represent the mean of three independent 
experiments; bars, ±S.E.M. (the standard error of the mean); *statistically significant 
(P<0.05), or **highly significant (P<0.005) differences obtained by comparing the 
sum effect of AD5-10 and carboplatin to a combination of both. C) Expression levels 
of activated caspase-8 and caspase-3 were determined by immunoblotting in 
untreated and treated OC cells using AD5-10 (1 µg/ml), carboplatin (100 µg/ml), or 
both. Data represent two independent experiments. CF, cleavage form. D) Dose 
response curve of carboplatin is presented using MDAH-2774 cells. MDAH-2774 OC 
cell line was incubated with the specified concentration of carboplatin, AD5-10 (1 
µg/ml), or both for 24 h, and apoptosis was determined. Columns represent the mean 
of four independent experiments; bars, ±SE; **statistically highly significant 
(P<0.005) differences obtained by comparing the sum effect of AD5-10 and 
carboplatin to a combination of both. EC50 values of carboplatin shifted from 105.5 
µg/ml to 172.6 µg/ml (95% confidence interval) in the presence of 1 µg/ml AD5-10. 
 
Carboplatin cooperates with AD5-10 to trigger apoptosis in OC cells by 
upregulation of DR5 
We then focused on the mechanism by which carboplatin cooperates with 
AD5-10 signaling to mediate enhanced tumor cell death. DR5 is a 
transcriptional target of p53 (23), and carboplatin has been shown to induce 
the p53 tumor suppressor pathway (24). In order to identify whether 
carboplatin cooperates with AD5-10 via upregulation of DR5 expression, we 
treated MDAH-2774 cells (overexpressing a mutated form of p53; Arg273His, 
(22)), A2780 cells (expressing wt p53, (20)), and ES-2 cells (expressing a 
mutated form of p53; S241F, (21)) with carboplatin and analysed the 
expression of p53 and DR5 by immunoblotting and flow cytometry, 
respectively (Fig. 3.1.2). The p53 status in selected OC cell lines was 
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confirmed by sequencing p53 in all three selected cell lines (data not shown). 
While DR5 expression levels were increased in all cell lines after carboplatin 
treatment, p53 expression was only increased in some (Fig. 3.1.2). Notably, 
DR5 expression (after treatment with carboplatin) and the apoptosis rate (after 
treatment with a combination of AD5-10 with carboplatin) in wt p53 cells were 
higher than in cells with mutant p53 (Fig. 3.1.2B and 3.1.1B respectively). 
These observations indicate that carboplatin forces expression of DR5 on OC 
cells, thereby enhancing their susceptibility to AD5-10-mediated apoptosis. In 
addition, MDAH-2774 harboured a mutant p53 allele; nevertheless, it showed 
a clear dose-dependent effect in vitro (Fig. 3.1.1B and D), illustrating that 
carboplatin also cooperates with AD5-10 regardless of the p53 status in OC 
cells. Thus, carboplatin treatment induced an increase in the expression of 
DR5 irrespective of the p53 status; hence, p53 mutations do not limit the 
therapeutic usefulness of combining AD5-10 with carboplatin. 
 
A) 
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B) 
 
Figure 3.1.2. Carboplatin cooperates with AD5-10 to trigger apoptosis in OC 
cells by upregulation of DR5. A) Selected OC cell lines were either untreated or 
treated with carboplatin (100 µg/ml) for 24 h. Expression of p53 was determined by 
immunoblotting; data represent two independent experiments. B) Flow cytometry 
analysis of DR5 expression on OC cell lines either untreated or treated with 
carboplatin (100 µg/ml) for 24 h; data represent three independent experiments. 
 
Combination of AD5-10 and carboplatin eradicates tumors in a xenograft 
OC mouse model 
To assess the antitumor efficacy of AD5-10 alone and/or in combination with 
carboplatin, we applied a tumor model of OC in xenograft-bearing mice. In this 
model, mice bearing subcutaneously established tumors were randomly 
grouped for treatment with vehicle, AD5-10, carboplatin, or a combination of 
AD5-10 and carboplatin. Treatment started on day 2, and tumor size was 
measured every second day after tumor inoculation. After two weeks, all 
tumor-bearing mice were sacrificed and tumor-free mice were maintained for 
another two weeks (Table 3.1.1). 
Mice treated with AD5-10 showed a clear reduction in tumor 
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progression compared to untreated mice (Fig. 3.1.3A and B). As expected, 
the treatment with carboplatin alone had no significant effect on tumor growth. 
In contrast, the combination of AD5-10 with carboplatin significantly 
suppressed tumor growth. Six out of seven treated mice (86%) remained 
tumor-free at the time of sacrificing (day 14th). After 28 days, >50% of mice 
(n=4) remained tumor-free following combined AD5-10 and carboplatin 
treatment (Table 3.1.1). Overall, our data suggest that AD5-10 in combination 
with carboplatin induces a high apoptosis rate in OC cells in vitro, and OC 
rejection in a significant number of mice in a xenograft model, whereas 
carboplatin alone has no significant effect (Fig. 3.1.1B and 3.1.3, and Table 
3.1.1). 
Significant differences in tumor volume between control and AD5-10 
treated mice were also observed. The largest reduction in tumor volume 
compared to the control group of untreated mice was observed in the group 
treated with AD5-10 in combination with carboplatin (Fig. 3.1.3A and C, and 
Table 3.1.1). Similar results were obtained for tumor weight (Fig. 3.1.3B). In 
contrast, mice receiving carboplatin alone did not display any statistically 
significant differences in tumor volume or tumor weight. Clearly, the tumor 
suppressive effect of AD5-10 alone and the elimination effect of AD5-10 in 
combination with carboplatin suggest that DR5 plays a strong antitumor role in 
carboplatin-resistant OC. 
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Table 3.1.1. Antitumorigenic effect of AD5-10 alone and/or in combination with 
carboplatin in a xenograft nude OC mouse model. 
 
 
A) 
 
 
B) 
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C) 
 
Figure 3.1.3. Combination of AD5-10 with carboplatin eradicates large, 
established tumors in a xenograft OC mouse model. A) 28 nude/nude mice were 
inoculated subcutaneously with 1.5x107 A2780 OC cell line into the left and right hind 
ventral flank (day 0). Random groups of seven mice each were then treated 
intraperitoneally with either saline (control tumor) or AD5-10 (10 mg/kg) on days 2, 6, 
9, 13, 16, and 20; carboplatin (100 mg/kg) on day 2; or a combination of AD5-10 and 
carboplatin at the respective doses and time as indicated above. Tumor volumes 
were measured every second day and on day 14 all tumor-bearing mice were 
sacrificed. Each measurement in each group is the sum of both left and right tumor 
volumes per animal and is included in the box plots. Box plots depict median values 
and the interquartile range, whereas dotted lines depict mean values in each group. 
Statistically significant differences * P<0.05, ** P<0.005 were determined by 
comparing tumor volume in the control group with treated groups. B) Tumor weight 
(after 14 days) in the four different groups; the median is indicated by a horizontal 
line. Each measurement in each group is the sum of both left and right tumor weight 
per animal. C) Representative mice and tumors of the indicated groups were 
assessed on day 14. 
 
AD5-10 enhances antitumor activity against OC in vivo 
We then evaluated the cytotoxic effect of administered substances on tumor 
tissues by immunohistochemical analysis. We observed a significant increase 
in caspase-3 activation and consequently in the apoptosis rate (measured by 
terminal deoxynucleotidyltransferase-mediated dUTP nick-end-labeling, 
TUNEL, assay) for AD5-10, but not for carboplatin, when compared to a 
control group (Fig. 3.1.4A and B). No significant differences in proliferation 
were observed for AD5-10 or carboplatin treatment (Fig. 3.1.3C). These data 
indicate that AD5-10 treatment induces apoptosis, consequently inhibiting the 
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growth of ovarian tumor tissue. 
DR4 is epigenetically silenced in the A2780 cells in vitro (19). To 
determine whether the observed effects are due to DR5 and not to DR4 e.g. 
by demethylation of the DR4 promoter and reconstitution of DR4 expression 
in vivo, we analysed the expression of DR4 in tumor tissues. 
Immunohistochemical and immunoblotting analysis showed no reconstitution 
of DR4 expression in vivo (Fig. 3.1.4D), indicating that TRAIL-induced 
apoptosis is only mediated by DR5. Furthermore, we analyzed the 
immunohistochemical expression of murine TRAIL using anti-mouse TRAIL 
antibody. Interestingly, we found that murine TRAIL to be highly expressed in 
tumor tissues (Fig. 3.1.4D). Remarkably, selected human OC cells do not 
express human TRAIL (Fig. 3.1.1A) and murine TRAIL was shown to have 
some cross-reactivity with human tumor cells (25). This finding might support 
our previous observation in humans that TRAIL is highly expressed in the 
tumor microenvironment of OC patients (7).  TRAIL is a key mediator of 
cytotoxic activity of activated NK cells and CD8+ lymphocytes (26), and is at 
least in part responsible for antimetastatic activities in vivo (27, 28). 
Immunohistochemical analysis revealed a dense infiltration of the tumor 
tissues with NK cells (Fig. 3.1.4D), suggesting that NK cells mediate 
cytotoxicity in OC by TRAIL-induced death. 
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D) 
 
Figure 3.1.4. AD5-10 enhances sensitivity of ovarian tumors to apoptosis. 
Immunohistochemical analysis of tumors obtained from mice inoculated with A2780 
OC cell line and sacrificed on day 14 (Fig. 3.1.3) for A) H&E and caspase-3 staining; 
B) Tunel assay; C) Ki-67 staining; and D) TRAIL ligand, DR4, and NK cell staining; 
magnification 20x. A) H&E staining showed vital solid intact tumor tissues in control 
and carboplatin-treated mice. In contrast, tumor cells from AD5-10 treated mice 
appeared damaged, leading to structural alteration and secondary bleeding. A and 
B) Proportional cell numbers in each micrograph (in caspase-3 staining, numbers of 
cleaved caspase-3 positive cells) are given as median values, and the interquartile 
range of 12 subsections of four different tumor sections per group is indicated within 
brackets. The median and interquartile range of the percentage of cleaved caspase-3 
and TUNEL positive cells are given below micrographs. Significant differences 
between the control group and the various treated groups are indicated: * P<0.05, ** 
P<0.005. C) Numbers given in the lower section show Ki-67-positive cells of nine 
subsections of three different tumor sections per group. Statistically significant 
differences are given as *P<0.05, comparing the control tumor group with the various 
treated groups. D) TRAIL staining (performed using goat anti-mouse TRAIL 
polyclonal antibody, AF1121 (R&D Systems)): vital tumor cells with weak diffused 
background staining of murine TRAIL, probably representing the soluble form of the 
molecule in control and carboplatin-treated tumor tissues. However, damaged tumor 
cells were observed in TRAIL positive AD5-10 treated tumor tissue. DR4 staining: 
tumor cells were consistently negative for DR4 in all tumor sections. Tissues from 
animal treated with AD5-10 showed granular-intercellular staining, which probably 
represents unspecific staining of degenerated apoptotic tumor cells. 4D11 staining: 
monoclonal antibody 4D11 (anti-Ly-49G2) revealed specific reactivity for mouse NK 
cells (16). Specific staining for NK cells was observed in all tumor sections. Damaged 
tumor cells were observed close to positive NK cells staining in AD5-10-treated but 
not in control or carboplatin-treated tumors. 
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AD5-10 cooperates with NK cells to suppress tumor growth of 
established OC in a xenograft mouse model 
We further explored the antitumor effect of AD5-10 in combination with TRAIL. 
Combination of TRAIL with AD5-10 enhances A2780 cellular sensitivity to 
TRAIL-induced apoptosis in vitro (Fig. 3.1.5A). Notably, AD5-10 antibody has 
been shown to bind to a different binding site than TRAIL (11). Therefore, 
AD5-10 does not compete with the TRAIL-binding site, which may explain a 
significantly increased rate of apoptosis observed after treatment with the 
combination of AD5-10 and human soluble TRAIL. 
Finally, we determined whether NK cell-mediated cytotoxicity is 
involved in AD5-10-induced effects. To do so, we made use of NK-cell-
depleting antibodies. Four groups of nude mice were subcutaneously 
inoculated with A2780 cells and were either left untreated or treated with AD5-
10 and/or NK1.1- and anti-asialo-depleting antibodies (Fig. 3.1.5B). Tumor 
development was observed for a period of 4 weeks. In NK-cell-depleted mice, 
AD5-10 had only a minimal effect on tumor growth (Fig. 3.1.5C), whereas 
AD5-10 significantly reduced tumor volume in the presence of NK cells (Fig. 
3.1.3A and 3.1.5C). This suggests that TRAIL expressed by active NK cells is 
required for AD5-10-induced apoptosis. This finding is in line with the fact that 
DR5 is more efficiently activated by secondary cross-linked trimers of TRAIL 
(29, 30). NK cell depletion alone had only a small effect on tumor growth, 
which might reflect the fact that A2780 cells are resistant to TRAIL-induced 
apoptosis (expressed via NK cells). Moreover, we found that NK cell numbers 
correlate with the survival of the animal, with a high NK cell number being 
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protective (Fig. 3.1.5D). In summary, these data suggest that the antitumor 
activity of AD5-10 depends on NK in OC. 
 
A) 
 
B) 
 
C) 
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D) 
 
Figure 3.1.5. Depletion of NK cells suppresses the tumoricidal effect of AD5-10 
on tumor outgrowth. A) A2780 OC cell line was incubated with the specified 
concentration of TRAIL, AD5-10 (1 µg/ml), or both for 24 h, and the apoptosis rate 
was measured. Columns represent the mean of three independent experiments; 
bars, ±SE; *statistically significant (P<0.05) difference obtained by comparing the 
sum effect of AD5-10 and TRAIL to a combination of both. B) Two groups of mice 
were depleted of NK cells by administration of polyclonal rabbit anti-asialo GM1 
antibody at a dose of 20 µl intraperitoneally every 4 days starting on day 3, and 
NK1.1 antibody 100 µg intraperitoneally every third day starting at day 3. A total of 
1x107 A2780 cells were inoculated subcutaneously into the left and right dorsal sides 
of the mice. Mice were treated intraperitoneally with AD5-10 or saline as indicated in 
Fig. 3.1.3A. Left panel: Histograms showing analysis of NK expression on 
splenocytes from NK-competent and NK-depleted mice. Numbers in dot plot 
quadrants indicate the percentage of NK-positive staining. Right panel: numbers of 
NK cells in NK-competent and NK-depleted mice are indicated. Each measurement 
in each group is included in the box plots showing the median; 25th and 75th 
percentiles; statistically highly significant differences **p<0.005 were determined by 
comparing the number of NK cells in NK-competent and NK-depleted groups. C) 
Tumor volumes in the four different groups were measured every second day. Mice 
were sacrificed when tumor size (at least in one flank) reached the required volume 
(~ 4000 mm3). Each measurement in each group is the sum of both left and right 
tumor volumes per animal. Data are represented as indicated in Fig. 3.1.3A. D) 
Correlation between NK cells (%) in depleted mice and life span.  
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Discussion  
The TRAIL pathway has been extensively studied in vitro and in vivo, and 
molecules targeting this pathway have become attractive candidates for 
anticancer treatment (10). Preclinical studies in mice provided the first 
evidence that the soluble form of recombinant TRAIL (rTRAIL) suppresses the 
growth of human tumor xenografts with no apparent systemic toxicity (31, 32). 
More  recently, rTRAIL has also entered clinical trials for the treatment of 
various malignancies (33). Although published phase 1 and 2 studies have 
indicated tolerated toxicity, the therapeutic efficiency is variable. In addition to 
the soluble ligand, several agonistic antibodies to the TRAIL functional 
receptors (DR4 or DR5) have been developed and entered into clinical trials 
in parallel (10). These agonistic antibodies may be more effective than the 
ligand at eradicating tumors for several reasons, one of them being the 
prolonged half-life time in vivo when compared to the recombinant proteins. 
Furthermore, the decoy receptors, which have been implicated in modulating 
the response to TRAIL, are not targeted by these ligands. Cross linking 
therapeutic antibodies might also overcome the resistance mechanisms to 
TRAIL-induced apoptosis observed in OC (5,13) according to the data in our 
study, which provides a novel link between NK-mediated immunosurveillance 
and activation of DR5-mediated apoptosis. 
DR5 was identified in 1997 (23, 34) and several DR5 agonistic 
antibodies exhibit a potent antitumor effect against TRAIL-sensitive tumor 
cells, but not against TRAIL-resistant tumor cells. These are currently in 
phase II evaluations in patients with advanced malignancies (35, 36). In the 
present study we used a DR5 agonistic antibody AD5-10 against TRAIL-
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resistant OC cells, and our results shed light on the postulated critical role of 
DR5 and NK-mediated immunosurveillance in OC progression. As expected, 
we observed limited cytotoxic effects on OC cells resistant to TRAIL-induced 
apoptosis in vitro upon stimulation with AD5-10 alone (Fig. 3.1.1B and C). We 
hypothesized that combined therapy with anti-DR5 and different 
pharmacological anticancer agents might induce more than additive antitumor 
activity. Our results showed that out of a number of agents used in the 
standard treatment of OC only the combination of AD5-10 with carboplatin 
displayed more than additive effect in vitro (Fig. 3.1.1B). This phenotype 
stimulated our interest in the nature of this mechanism. Consequently, we 
determined the cytotoxic effect of AD5-10 alone or in combination with 
carboplatin in a platin-resistant OC mouse model. While there was, as 
expected, no effect of carboplatin alone, an effect of AD5-10 was observed. 
Importantly, the combination of AD5-10 with carboplatin eventually eliminated 
OC (Fig. 3.1.3A, B, and C; and Table 3.1.1) in a significant number of 
animals. Chemotherapeutic agents have been shown to cooperate with the 
TRAIL ligand to enhance apoptosis (37). However, the molecular basis behind 
such cooperation has not yet been elucidated. One mechanism (probably not 
the only one) is based on our observation that carboplatin cooperates with 
AD5-10 by upregulating DR5 expression regardless of the p53 status (Fig. 
3.1.2). However, this finding does not fully explain the exceptional activity of 
AD5-10 and carboplatin in vivo and makes it necessary to consider the activity 
of these substances in the context of the immune system. 
As postulated previously the TRAIL pathway plays a key role in tumor 
surveillance (7, 26-28). Understanding the activity of a potential agent 
Results and Discussion 
   57 
targeting this pathway requires putting a spotlight on the activity of the hosts’ 
immune system as reflected in the tumor microenvironment. Our previously 
published data support a key role of TRAIL and the functional TRAIL 
receptors in OC, showing increased survival in patients expressing a high 
level of TRAIL in tissue adjacent to the tumor (7, 19). However, the origin of 
this expression has not been fully evaluated to date. In our current study we 
addressed the role of NK cell-mediated effects of DR5-induced apoptosis. We 
recorded that AD5-10 alone did not have a significant effect on apoptosis; 
however, it had a more than additive effect when combined with human 
soluble TRAIL in vitro to enhance TRAIL-mediated cytotoxicity (Fig. 3.1.5A). 
Moreover, we observed that TRAIL and NK cells are highly expressed in the 
tumor microenvironment (Fig. 3.1.4D), and that depletion of NK cells from 
mice bearing tumors led to increased tumor growth and also abolished the 
cytotoxic effect of AD5-10 (Fig. 3.1.5C and D). These findings indicate that 
TRAIL expressed on active NK cells might cross link AD5-10, suggesting that 
DR5 is more efficiently activated by secondary cross-linked trimers of soluble 
TRAIL than by non-cross-linked molecules (Fig. 3.1.5A, and (29, 30)). 
Notably, AD5-10 antibody binds to a different binding site than TRAIL cells 
(11), and murine TRAIL was shown to have some cross-reactivity with human 
tumor cells (25). However, other mechanisms like upregulation of DR5 on OC 
cells by carboplatin and targeting by AD5-10 efficiently activated cell killing 
without the need for secondary cross linking (Fig. 3.1.1B and C). In fact, 
according to our data, forced expression of DR5 in the presence of TRAIL-
expressing NK cells provides an ideal environment for highly efficient 
activation of DR5 by AD5-10. This fact is supported by eradication of 
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implanted tumors in an NK-competent xenograft OC mouse model (Fig. 
3.1.3A and Table 3.1.1), and by the abolished cytotoxic activity of AD5-10 in 
NK-depleted mice (Fig. 3.1.5C and D). This finding clearly confirms the 
importance of NK-mediated immunosurveillance in OC in a preclinical mouse 
model. Agonistic DR5 antibodies probably act together with naturally 
occurring TRAIL ligand to overcome the resistance mechanisms that develop 
during tumorigenesis. 
Our study highlights the lack of knowledge regarding the interplay 
between therapeutic agents, host immunity, and the evasion mechanisms 
developed by individual tumors. Only an improved understanding of these 
basic mechanisms will ultimately lead to tailored patient selection and the 
choice of combination partners for drugs targeting the TRAIL pathway. 
Carboplatin and AD5-10 seem to be a promising regimen for future clinical 
trials in platin-resistant OC. 
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3.2. The role of c-FLIPL in ovarian cancer: chaperoning 
tumor cells from immunosurveillance and increasing 
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Abstract 
Activation of tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) functional receptors by their ligand induces apoptosis through 
activation of caspase-8. Cellular Fas-associated death domain-like interleukin-
1β-converting enzyme (FLICE)-like inhibitory protein (c-FLIP) blocks TRAIL-
mediated apoptosis through inhibition of caspase-8 activation. The current 
study is based on our previous observations that about 40% of OC patients 
express high levels of c-FLIPL, and that natural killer (NK) cells mediated 
immunosurveillance in OC. In the present study, we observed that the 
knockdown of c-FLIPL in human OC cell lines not only enhanced their 
sensitivity to TRAIL mediated-apoptosis, but also inhibited their migratory 
phenotype in a TRAIL-dependent manner in vitro. Shutdown of c-FLIPL in OC 
cells significantly decreased tumor development by induction of apoptosis and 
reduction of proliferation in vivo. Importantly, the knockdown of c-FLIPL 
particularly inhibited the invasion of OC cells into the peritoneal cavity, which 
might be due to high expression of TRAIL by NK cells and NK-cell mediated 
immunosurveillance. These data demonstrate that c-FLIPL exhibits multiple 
functions in OC cells: first by concomitantly evading the natural immunity 
mediated by TRAIL-induced cell death, second by augmenting cell motility 
and invasion in vivo. Our findings indicate that c-FLIPL regulates sensitivity of 
OC to TRAIL-mediated apoptosis and offers possible therapeutical 
implications for OC in the future. 
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Introduction 
Apoptosis is a physiological process playing a fundamental role not only in 
controlling cell differentiation and tissue homeostasis, but also in eliminating 
cells that undergo uncontrolled cellular proliferation [1-4]. Caspases, a family 
of cysteine proteinases, are key elements in apoptosis [5, 6]. So far, at least 
10 caspases have been reported [5], each encoding sequences essential for 
proteolytic activity and induction of apoptosis. Activation of the caspase 
cascade is triggered by various death signals, subsequently leading to 
apoptotic cell death. 
Death receptors such as APO-1/FAS or functional tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors exhibit an 
intracellular sequence denoted as death domain (DD). The adaptor protein 
Fas-associated death domain protein (FADD) is recruited to the death 
receptors by homotypic DD interaction [7]. Ligation of death receptors by their 
cognate ligands leads to recruitment of FADD, which in turn leads to 
activation of caspase-8, further resulting in assembly of the death-inducing 
signaling complex (DISC) initiating the apoptotic cascade [8]. 
The apoptosis signaling pathway induced by death receptors is 
regulated by inhibitor proteins at distinct steps. Among these proteins is the 
cellular Fas-associated death domain-like interleukin-1β-converting enzyme 
(FLICE)-like inhibitory protein (c-FLIP). c-FLIP interferes with activation of pro-
caspase-8 most proximal to the plasma membrane [9, 10]. Eleven distinct 
isoforms of c-FLIP produced by alternative splicing at the RNA level have 
been described. Of these, two splice variants, the long c-FLIPL and the short 
isoform c-FLIPS, were found to exhibit different molecular mechanisms for 
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inhibiting the activation of pro-caspase-8 at the protein level [10-13]. While c-
FLIPS inhibits activation of pro-caspase-8 by blocking cleavage for processing 
the active form, c-FLIPL triggers the first cleavage of pro-caspase-8 resulting 
in the large and small subunit [14]. c-FLIP was found to be highly expressed 
in various human tumors such as melanoma [10, 15, 16] and ovarian cancer 
(OC) [17]. c-FLIPL was shown to prevent natural killer (NK) cells and cytolytic 
T lymphocytes (CTLs)-mediated cell killing via Fas ligand (FasL), resulting in 
escape of immunosurveillance and establishment of aggressive tumors in vivo 
[18-20]. In this regard, we have shown recently that NK cells play an essential 
role in immunosurveillance of OC [21], and that c-FLIPL is upregulated in OC 
patients [17]. 
 So far, several intracellular signaling pathways, including ERK, 
AKT/PI3K, and NF-κB pathways [22-24] were shown to regulate c-FLIP 
transcription and posttranslational regulation. Moreover, p53 was shown to 
inhibit c-FLIP expression [25, 26]. 
In the present study, we deciphered the role of c-FLIPL in OC. We 
report that removal of c-FLIPL from TRAIL-resistant OC cells not only 
enhances sensitivity to TRAIL-induced apoptosis, but also inhibits tumor 
growth in vitro as well as in vivo. We found that downregulation of c-FLIPL 
inhibits migration of OC cells in presence of soluble TRAIL in vitro, and 
abolishes the invasive behaviour of ovarian tumors in vivo. Altogether, our 
data highlight c-FLIPL as a key regulatory protein in ovarian tumor 
progression. 
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Material and Methods 
Cell lines 
Human OC cell lines MDAH-2774 (ovarian endometroid adenocarcinoma 
(OEA)-derived cell line, derived from the ascitic fluid of a patient [27], and a 
platin resistant sub-line of the OC cell line A2780 (human epithelial OC cell 
line established from tumor tissue [28]) were used in our study. Cell lines were 
cultured in RPMI medium supplemented with 10% fetal calf serum (FCS) 
(PAA Laboratories GmbH, Pasching, Austria) and 0.1% penicillin/streptomycin 
(PAA Laboratories GmbH). The cell line MDAH-2774 was obtained from the 
American Type Culture Collection (ATCC, VA, USA), and the cell line A2780 
was obtained from the European Collection of Cell Cultures (ECACC, 
Wiltshire, UK). 
 
RNA interference (RNAi) 
Oligonucleotides encoding short hairpin RNAs (shRNAs) targeting c-FLIP 
were designed (Sigma-Aldrich, MO, USA) to hold restriction sites for BamH1 
and HindIII at their 5' and 3' end, respectively. The annealed oligonucleotides 
were cloned into BamH1 and HindIII of pSilencer 4.1-CMV neo vector 
(Applied Biosystems, CA, USA). Cloning of resulting vectors was verified by 
sequencing. The specificity of the shRNA was confirmed using two 
oligonucleotides targeted to different regions of the mRNA: oligo 1 
(nucleotides 514-534 ORF): 5'-
GATCCGCAGTCTGTTCAAGGAGCATTCAAGAGATGCTCCTTGAACAGAC
TGCTTA-3' [29]. Oligo 2 (nucleotides 29-49) 5'-
GATCCGAAGCACTTGATACAGATGTTCAAGAGACATCTGTATCAAGTGCT
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TCTTA-3' [30]. Each of the shRNA suppressed the encoded protein and 
exerting the same effects. shRNA control was used to confirm that the 
observed effects are indeed specific and due to c-FLIPL suppression by RNAi. 
The control was designed in a way to avoid targeting of any protein coding 
gene product. 
Selected OC cell lines were transfected with the corresponding vectors 
utilizing the Lipofectamine method according to the manufacturer's 
instructions (Lipofectamine 2000; Invitrogen, CA, USA). Stable clonal 
transfectants were generated, and the efficiency of downregulation was 
confirmed by quantitative reverse transcription-polymerase chain reaction and 
Western blot. 
 
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-
PCR) 
Total RNA was isolated from parental and genetically manipulated OC cell 
lines by RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer's instructions. RNAs were then quantified by Nano Chips (Lab-
on-a-Chip, Agilent Technologies, CA, USA). Subsequently, cDNAs were 
generated by reverse transcription of isolated mRNAs using SuperScript II 
RNase H- Reverse Transcriptase (Invitrogen, CA, USA) according to the 
manufacturer's instruction. Quantitative real time PCR was performed using 
the following Assay On Demand probes: c-FLIP, Hs00153439_m1; HPRT1, 
Hs99999909_m1 purchased from Applied Biosystem (CA, USA). qRT-PCR 
Master MIX (Eurogentec, CA, USA) was used to perform the qRT-PCR. The 
qRT-PCR was performed on a 7900HT Sequence Detection System (Applied 
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Biosystems) applying the following program: 50°C for 2 minutes and 95°C for 
10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. Relative expression was calculated from the threshold cycles (Ct) 
obtained with the SDS 2.2 Software (Applied Biosystems) as follows: 2^–
[(Ctgene mean of duplicated probes – Ctgene mean of duplicated calibrator) – 
(CtHPRT1 mean of duplicated probes – CtHPRT1 mean of duplicated calibrator)]. 
 
Western blot 
Western blot was performed as described previously [21] using the following 
primary antibodies: mouse monoclonal anti-human c-FLIP (NF6; dilution 
1:500; Alexis, Lausen, Switzerland), and goat anti-actin polyclonal antibody 
(dilution 1:500; Santa Cruz, CA, USA). 
 
Determination of apoptosis 
Parental as well as genetically manipulated MDAH-2774 and A2780 OC cell 
lines were plated at a density of 5 x 104 cells/well in 24-well plates and 
incubated for 24 hours prior to stimulation. Then cells were treated with 
soluble TRAIL (Alexis) 100 ng/ml for 24 hours. Cells were harvested by 
trypsinization using 0.05% trypsin and 0.02% EDTA without Ca2+ and Mg2+ 
(PAA Laboratories GmbH). Apoptosis was measured by an annexin V-FITC 
apoptosis detection kit (Alexis) according to the manufacturer’s instructions. 
Flow cytometry of annexin V-FITC and Propidium Iodide (PI) staining was 
performed using FACScan (Becton Dickinson, Heidelberg, Germany) with 
CELLQuest Pro software. 
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Proliferation assay 
Selected OC cell lines were plated at a density of 5 x 10 3 in 100 µl of culture 
medium in a 96-well plate and were left to adhere. Cells were then incubated 
for 24 to 72 hours. Cell viability was measured by CellTiter-Blue® Assay 
(Promega, WI, USA) according to the manufacturer's instructions. The 
fluorescence signal was recorded using a Wallac 1420 VICTOR2 
fluorescence plate reader (Perkin Elmer, MA, USA). Three independent 
experiments, each in triplicate, were performed. 
 
In vitro migration assay 
Migration assays were performed using a 24-well trans-well cell culture 
chamber (BD Biosciences, CA, USA) according to the manufacturer's 
instructions. Briefly, 500 µl of selected OC cells were suspended in the upper 
chamber at a final concentration of 5x104 cells/ml in duplicate. One group was 
left untreated and the other was supplemented with 100 ng/ml medium of 
soluble TRAIL. The lower chamber contained 30% FCS/culture medium. After 
24 hours incubation, the OC cells on the upper surface were removed by 
wiping with cotton swabs, and the migrated cell on the lower surface were 
stained with mounting medium for fluorescence with DAPI (Vector 
Laboratories, Inc., CA, USA). The number of cells on the lower surface of the 
filters was counted under a fluorescence microscope (Nikon Eclipse 800, 
Tokyo, Japan) equipped with a Nikon DS-R1 camera, using the NIS-Elements 
software. Three independent experiments, each in duplicate, were performed. 
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Xenograft animal model 
4-6 week-old female athymic nude-Foxn1 nu/nu mice were obtained from 
Harlan (Udine, Italy) and maintained under specific pathogen-free conditions 
at the animal resource service of the Medical University of Vienna. Mice were 
subcutaneously inoculated with 1.5 x 107 A2780 OC cells on both ventral hind 
flanks. Tumor size was measured every second day by calipers. The tumor 
volume was calculated according to the formula V=4/3 x π x (L/2 x W/2 x 
W/2); L, length; W, width [31]. Mice were sacrificed two weeks after 
inoculation. Tumors were recovered, weighed and further processed for 
histological and pathological analysis. Animal experiments were performed 
according to protocols approved by the Austrian Federal Ministry for 
Education, Science and Art. 
 
Immunohistochemistry 
Formalin fixed, paraffin embedded sections were deparaffinized, rehydrated 
and cooked in 10 mmol citrate buffer (pH 6,0) for 20 minutes. To inhibit 
endogenous peroxidase, slides were incubated in 0.3% hydrogen peroxide. 
Serum was used to block background staining. Sections were subsequently 
incubated with the following primary antibodies: anti-human Ki-67 (clone MIB-
1; dilution 1:200; Dako, CA, USA) for 1 hour, c-FLIPL (C-19; dilution 1:25; 
Santa Cruz; this antibody shows non cross-reactivity with FLIPS) for 1 hour. 
The secondary biotinylated antibody was applied corresponding to the source 
of the primary antibody. Then the Strep-ABComplex (Dako) was added for 45 
minutes and DAB (Dako) was used for color development and Mayer’s 
hematoxylin for counterstaining. Tissue sections were analyzed on an 
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Olympus BX50 upright light microscope (Olympus Europe, Hamburg, 
Germany) equipped with the Soft Imaging system CC12. 
 
Tunel Assay 
Apoptosis was determined by terminal deoxynucleotidyltransferase-mediated 
dUTP nick end labeling (TUNEL; Roche, Manchester, UK) according to the 
manufacturer’s instructions. Cells were analyzed on a fluorescence 
microscope (Nikon Eclipse 800) equipped with a Nikon DS-R1 camera, using 
the NIS-Elements software. 
Positive and negative controls were performed by treating samples with 
DNase I or excluding incubation with primary antibody, and yielded positive 
and negative results, respectively. The percentage of positive cells was 
determined by a blinded operator. 
 
Statistical analysis 
Statistical significance was assessed by two-sided Student’s t-tests using R 
and Statstoft’s Statistica software (Hamburg, Germany). Data were visualized 
with box plots or bar plots. P values below 0.05 were considered as 
statistically significant, and P values below 0.005 were considered highly 
significant. The correlation between variables was estimated using the 
Pearson correlation coefficient. 
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Results 
c-FLIPL depletion sensitizes OC cells for TRAIL-induced apoptosis 
We previously showed that more than two third of OC patients display defects 
in the TRAIL pathway, including downregulation of TRAIL functional receptors 
DR4 and/or DR5, as well as upregulation of c-FLIPL [17]. Based on these 
finding we intended to decipher the physiological function and intracellular 
regulation of c-FLIPL in OC development. We applied a loss of function 
approach via expressing shRNA for depleting c-FLIPL expression in OC cell 
lines. We expressed shRNA from two different c-FLIPL sequences (shRNA1 
or shRNA2) in two human OC cell lines, namely MDAH-2774 and A2780. 
These cell lines are highly resistant to TRAIL-induced apoptosis, and harbor 
various alterations ranging from non-functional p53 in MDAH-2774 [32], and 
silencing of DR4 expression in A2780 (Supplementary Fig. 3.2.1) [33]. The 
shRNA reduced the expression of c-FLIPL protein significantly, as 
demonstrated by immunoblotting (Fig. 3.2.1A). Respective mRNA expression 
levels were reduced by 61% and 55% in MDAH-2774, and by 63% and 46% 
in A2780 in both c-FLIP shRNA1 and c-FLIP shRNA2 when compared to 
control shRNA (Fig. 3.2.1B and Supplementary Fig. 3.2.2A). c-FLIPL 
expression remained unaltered in MDAH-2774 and A2780 cell lines 
expressing a control shRNA not targeting a protein coding transcript when 
compared to parental cells (Fig. 3.2.1A and B). 
We found that depletion of c-FLIPL increased the apoptosis rate of c-
FLIP shRNA1 and c-FLIP shRNA2 in MDAH-2774 and A2780 OC cell lines 
significantly when compared with parental and control shRNA cells in a 
TRAIL-dependent manner in vitro (Fig. 3.2.1C and D, and Supplementary Fig. 
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3.2.2B). Next, we wanted to determine whether the genetic alterations 
introduced into OC cells affected their proliferation. c-FLIP shRNA1, c-FLIP 
shRNA2, control shRNA and parental cells from MDAH-2774 and A2780 OC 
cells were seeded into 24-well plate and the proliferation rate was determined 
every 24 hours for 4 days. No significant differences were found in c-FLIPL 
depleted cells compared to either control shRNA or parental counterparts in 
vitro (Fig. 3.2.1E). 
Together, these data show that downregulation of c-FLIPL significantly 
enhanced the susceptibility of OC cells to TRAIL-induced apoptosis in vitro. 
 
A) 
       
 
B) 
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D) 
 
E) 
    
Figure 3.2.1. c-FLIPL depletion sensitizes OC cells for TRAIL-induced 
apoptosis. A) MDAH-2774 and A2780 OC cells were either left untransfected or 
were transfected with a vector encoding control shRNA or c-FLIP shRNA1. Protein 
expression of c-FLIPL and actin, used as housekeeping protein, were assessed by 
Western blot. A representative experiment for two independent experiments is 
shown. B) RNAs were isolated from untransfected MDAH-2774 and A2780 OC cells 
and those transfected with a vector encoding control shRNA or c-FLIP shRNA1. 
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qRT-PCR was performed using specific primers for c-FLIP and HPRT1, used as 
housekeeping gene. Columns represent the mean of duplicate of one experiment; 
bars, ±S.E.M. (standard error of the mean). Data represent three independent 
experiments. C) Parental A2780 cells or those transfected with control shRNA or c-
FLIP shRNA1 were either left untreated or treated with soluble TRAIL (100 ng/ml) for 
24 hours. Apoptosis was determined by annexin-V and PI staining. The percentage 
of apoptotic cells in the respective quadrant is given. D) Parental MDAH-2774 and 
A2780 OC cells or those transfected with control shRNA or c-FLIP shRNA1 were 
either left untreated or treated with soluble TRAIL (100 ng/ml) for 24 hours, and 
apoptosis was measured as indicated above. Columns hold the mean of three 
independent experiments: bars, ±S.E.M.; *statically significant (P<0.05), or **highly 
significant (P<0.005) differences obtained by comparing c-FLIP shRNA1 transfected 
cells to either parental or control shRNA transfected cells. E) In vitro cell proliferation 
assay. The proliferation rate of MDAH-2774 and A2780 parental cells or those 
transfected with control shRNA or c-FLIP shRNA1 was determined by Cell Titer-Blue 
for 24, 48 and 72 hours. The experiment was performed in triplicate, columns 
represent the mean of triplicate of one experiment; bars ±S.E.M. Data represent 
three independent experiments. 
 
c-FLIPL depletion causes regression of OC in a xenograft mouse model 
We next evaluated the effects of c-FLIPL depletion on OC progression in vivo. 
We used the A2780 human epithelial OC cell line, representing the most 
common category of human OC, to establish a xenograft OC mouse model. 
We subcutaneously implanted c-FLIP shRNA1, control shRNA expressing 
cells, or parental cells (1.5 x 107) into 6 to 8-week-old female athymic mice, 
and monitored tumor growth. All mice were sacrificed after 2 weeks and tumor 
weights were determined. We observed that both parental (n=5) and control 
shRNA cells (n=8) formed very large tumors within 2 weeks, whereas mice 
injected with c-FLIP shRNA1 cells showed either no tumor (n=4) or reduced 
tumor formation (n=4) (Fig. 3.2.2A, and Supplementary Fig. 3.2.3A). These 
results were obtained from two independent experiments. In contrast to both 
parental and control shRNA cells, which showed large tumor weight, c-FLIP 
shRNA1 cells resulted in significantly reduced tumor weight (Fig. 3.2.2C and 
Supplementary Fig. 3.2.3C). The correlation between tumor volume (day 14) 
and tumor weight was high (Pearson r=0.84 and 0.87, Fig. 3.2.2B and 
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Supplementary Fig. 3.2.3B respectively). These results indicate that c-FLIPL 
expression promotes OC development in vivo, giving new insights about the 
physiological role of c-FLIPL in ovarian tumor progression in vivo. 
 
A) 
 
B) 
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Figure 3.2.2. c-FLIPL depletion causes regression of OC in a xenograft mouse 
model. A) Groups of five female nude/nude mice were subcutaneously inoculated 
with 1.5 x 107 of either parental A2780 ovarian tumor cells or those transfected with 
control shRNA1 or c-FLIP shRNA1 into left and right ventral hind flanks (day 0). 
Tumor volumes were measured every second day for a period of 14 days. Every 
measurement in each group represents the sum of both left and right tumor volumes 
per animal and is depicted by box plots; the line inside each boxplot indicates 
median, and the boxes at the 25th and 75th percentiles indicate error bars at minimum 
and maximum, respectively. * P<0.05,  ** P<0.005, comparing tumor volume in c-
FLIP shRNA1 group with either parental or control shRNA groups. B) Correlation 
between tumor volume on day 14 and tumor weight. C) The tumor weight of the 
given groups after 14 days is depicted by box plots; * P<0.05, ** P<0.005, comparing 
the c-FLIP shRNA1 group with parental or control shRNA groups. Weight 
measurement in each group is represented by the sum of both left and right tumors 
per animal. 
 
c-FLIPL depletion enhances sensitivity of ovarian tumors to apoptosis 
and inhibits proliferation in vivo 
We analyzed whether the suppressive effect of c-FLIPL depletion on ovarian 
tumor growth in vivo is due to increased apoptosis or reduced proliferation. 
Histological analyses confirmed that the number of vital, intact cells was 
markedly reduced in mice injected with c-FLIP shRNA1 when compared to 
control shRNA or parental cells, indicating that c-FLIPL depletion influenced 
tumor cell survival (Fig. 3.2.3A). c-FLIPL was markedly reduced in c-FLIP 
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shRNA1 compared to control or parental tumor tissues, again confirming 
effective depletion of c-FLIPL (Fig. 3.2.3A). 
 Interestingly, immunohistochemical analysis of tumor tissues showed 
that c-FLIP shRNA1 expressing tumors displayed a reduction in Ki-67 
(indicator for cell proliferation) positive cells when compared to control shRNA 
and parental cells (Fig. 3.2.3A and B). Moreover, the apoptosis rate was 
significantly increased from 4% in parental and control shRNA to 27% in c-
FLIP shRNA1 expressing cells (Fig. 3.2.3A and C). This observation reflects 
the finding mentioned above that c-FLIPL restores sensitivity of OC to TRAIL-
induced apoptosis (Fig. 3.2.1C and D, and Supplementary Fig. 3.2.2B). Taken 
together, these data indicate that the antitumorigenic effects observed in mice 
implanted with c-FLIP shRNA1 are in fact not only due to induction of 
apoptosis, but also due to inhibition of proliferation. Our finding indicates that 
c-FLIPL is indeed an apoptosis inhibitor as well as a proliferation mediator in 
vivo. 
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Figure 3.2.3. c-FLIPL depletion enhances sensitivity of ovarian tumors to 
apoptosis and inhibits proliferation in vivo. Immunohistochemical analysis of 
tumors obtained from mice on day 14 transplanted with either parental A2780 cells or 
cells transfected with control shRNA or c-FLIP shRNA1 for A) H&E, c-FLIPL, Ki-67 
staining, and Tunel assay; magnification 200x. B and C) Proportional cell numbers of 
positive staining of 9 subsections of three different tumor sections per group are 
depicted by box plot; *statistically significant (P<0.05), or **highly significant 
(P<0.005) differences when comparing the c-FLIP shRNA1 group with parental or 
control shRNA groups. 
 
c-FLIPL depletion inhibits migration and the invasive behavior of OC 
cells  
We examined whether c-FLIPL depletion has an effect on the migratory 
phenotype of OC cells in vitro. c-FLIP shRNA1, control shRNA, and parental 
A2780 cells were grown in absence or presence of 100 ng/ml TRAIL for 24 
hours, and the number of migrated cells through chambers was determined. 
We found that the depletion of c-FLIPL by shRNA completely inhibited 
migration of OC cells (98.7%), whereas cells treated with control shRNA or 
parental cells were not inhibited in presence of soluble TRAIL (38%) (Fig. 
3.2.4A and B). Importantly, no differences in migration were observed 
between the tested groups in absence of TRAIL (Fig. 3.2.4A and B), which 
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might suggest that the observed inhibitory effects are indeed due to the 
increase of apoptosis upon downregulation of c-FLIPL. Moreover, this result 
confirms the increase in apoptosis rate which was observed after c-FLIPL 
depletion and treatment with soluble TRAIL (Fig. 3.2.1C and D, and 
Supplementary Fig. 3.2.2B). Together, these data indicate that c-FLIPL 
inhibits TRAIL-induced apoptosis, and also permits migration of OC cells in 
presence of TRAIL. 
We finally examined whether c-FLIPL-mediated tumor growth is 
required for the invasive phenotype of OC in vivo. We subcutaneously 
inoculated control shRNA and c-FLIP shRNA1 expressing cells into athymic 
nude mice. Two weeks after inoculation we observed that control shRNA 
tumors inoculated into mice (n=4) invaded the peritoneal cavity, whereas no 
invasive tumors were observed in mice inoculated with c-FLIP shRNA1 
expressing tumors (n=3) (Fig. 3.2.4C). This finding is in line with our 
observation outlined above that c-FLIPL depletion inhibits migration of OC 
cells in the presence of soluble TRAIL (Fig. 3.2.4A and B). Taken together, 
these results indicate that the expression of c-FLIPL promotes tumor 
development, furthermore acquiring the ability to invade the peritoneal cavity.  
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B) 
 
 
C) 
 
Figure 3.2.4. c-FLIPL depletion inhibits migration and the invasive behavior of 
OC cells. A) In vitro migration assay. Parental A2780 cells, transfected with control 
shRNA, or with c-FLIP shRNA1 were either left untreated or treated with soluble 
TRAIL (100 ng/ml), and their migratory potential was assessed in 24-well transwell 
cell culture chambers for 24 hours. Migrated cells were counted by staining the lower 
surface of the membrane with DAPI. Data represent three independent experiments. 
B) The number of migrated cells is shown in presence or absence of soluble TRAIL. 
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Data represent three independent experiments. C) Groups of five female nude/nude 
mice were subcutaneously inoculated with 1.5 x 107 A2780 ovarian tumor cells 
expressing either control shRNA or c-FLIP shRNA1 into left and right ventral hind 
flanks (two mice of the group inoculated with c-FLIP shRNA1 were excluded from the 
analysis as inoculation resulted in intraperitoneal tumors). In contrast to A2780 OC 
cells transfected with c-FLIP shRNA1, cells transfected with control shRNA invaded 
the peritoneal cavity of nude mice. 
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Discussion 
TRAIL is known to induce apoptosis in transformed cells but not in normal 
cells. There are several potential resistance mechanisms that protect normal 
cells from the cytotoxic effect of TRAIL, including expression of decoy 
receptors (DCR1 and DCR2), or the presence of apoptosis inhibitor proteins 
such as c-FLIP. The expression of functional TRAIL protein appears to be 
restricted to immune cells. Moreover, TRAIL-deficient mice do not show large 
abnormalities, except for impaired tumor immunosurveillance and higher 
sensitivity to experimental autoimmune diseases [34]. These findings provide 
strong evidence for the physiological role of TRAIL in the immune system. NK 
cells and CTLs both have the ability to destroy tumor cells by various 
mechanisms; one of them is the production of death ligands such as FasL and 
TRAIL. As published previously, c-FLIPL prevents NK cells and CTLs-
mediated immunosurveillance, resulting in aggressive tumors in vivo [18-20]. 
We have recently shown that TRAIL is highly expressed in the ovarian tumor 
microenvironment, and NK-mediated immunosurveillance in OC might be 
mediated by TRAIL [21]. We further wanted to investigate the role of c-FLIPL 
in inhibiting TRAIL-induced apoptosis and in mediating OC progression. 
Initially, we examined expression values of c-FLIP in gene expression 
datasets in human primary ovarian tumors as stored in the Oncomine 
database [35]. The expression level of c-FLIP was found to be upregulated in 
various ovarian tumors (endometrioid, serous, mucinous, and clear cell 
carcinomas) when compared to normal ovarian tissue samples in a dataset 
published by Lu [36]. These observations in human primary ovarian 
carcinoma are in line with previous findings that c-FLIPL is highly expressed in 
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primary ovarian tumors [17, 37]. Actually, c-FLIP has been suggested to 
mediate proapoptotic as well as antiapoptotic effects [9, 10, 13, 38, 39]. 
Nonetheless, proapoptotic effects were observed mainly upon transient, 
forced expression, which may have been due to high cytoplasmic levels of c-
FLIP. This in turn may have mediated activation of procaspase-8 [40]. Results 
from stably forced expression of c-FLIP and from c-FLIP knockout mice 
supported the anti-apoptotic effect [10, 41]. In the current study, we showed 
that c-FLIPL mediates anti-apoptotic signals in ovarian tumor malignancy 
using OC cell lines resistant to TRAIL-mediated apoptosis. We found that 
depletion of c-FLIPL in OC cell lines breaks the resistance mechanism to 
TRAIL-induced apoptosis in vitro. We observed that depletion of c-FLIPL in 
MDAH-2774 cells enhanced sensitivity to TRAIL-induced apoptosis to about 
25%, and in A2780 cells to about 45% (Fig. 3.2.1 and Supplementary Fig. 
3.2.2). 
In the preclinical xenograft mouse model we found that the shut down 
of c-FLIPL reduced tumor development (Fig. 3.2.2A and C, and 
Supplementary Fig. 3.2.3A and C). Tumor volume and tumor weight were 
dramatically reduced in c-FLIPL depleted cells when compared to cells given 
control shRNA, or parental cells. Moreover, we found that c-FLIPL depletion 
increased the rate of apoptosis in tumor cells implanted in mice (Fig. 3.2.3A 
and C). These in vivo results, next to our in vitro data, indicate the key role of 
c-FLIPL in inhibiting apoptosis in OC via mediating the escape of ovarian 
tumors from immunosurveillance. Remarkably, nude mice are characterized 
by a higher cytotoxic activity of NK cells and macrophages than their euthymic 
counterparts [42, 43]. Therefore we preferred nude mice for our studies over 
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other immune deficient animal models. The homology between the human 
and murine TRAIL ligand is only 65%; however, murine TRAIL was shown to 
have some cross-reactivity with the receptors on human tumor cells [44]. 
Interestingly, we found that c-FLIPL depletion has no effect on 
proliferation and migration of OC cell lines in absence of soluble TRAIL in 
vitro. However, our in vivo results showed that depletion of c-FLIPL decreased 
the rate of proliferation in ovarian tumor tissues (Fig. 3.2.3A and B). Several 
lines of evidence support such a role for c-FLIPL in induction of proliferation: 
First, studies applying gain of function showed that c-FLIPL activates ERK and 
NF-κB -mediated T-cell proliferation [45-47]. Second, conditional removal of c-
FLIP in mouse T-cells displayed a decrease in TCR-activated proliferation and 
IL-2 production, which has been linked to a defect in NF-κB signaling [45, 48]. 
Third, c-FLIPL has been shown to mediate T-cell proliferation through an NF-
κB -independent mechanism, which still needs to be further illustrated [49]. In 
our study, we did not observe any alterations in proliferation of c-FLIPL 
depleted OC cells in vitro (Fig. 3.2.1E), which might be explained by the fact 
that the specific microenvironment is absent in vitro. We noted that in the 
presence of soluble TRAIL, c-FLIPL depletion completely inhibited the 
migratory behavior of OC cells (Fig. 3.2.4A and B), and inhibited the invasive 
behavior in vivo. This observation indicates that c-FLIPL depletion induces 
apoptosis in OC cells (Fig. 3.2.4), which might be the reason that these cells 
do not go through the peritoneal cavity and therefore inhibits their invasive 
behavior. Additionally, c-FLIPL has been shown to regulate ERK and NF-κB 
pathways [46], which might explain why c-FLIPL induces OC invasion. 
Notably, OC in humans metastasizes in most cases into the free peritoneal 
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cavity and is restricted to the peritoneal cavity. Metastases at other sites are a 
rare event, which is in line with our observations in the xenograft mouse 
model that also showed invasion restricted to the peritoneal cavity and not 
other sites. 
 In conclusion, our in vitro and in vivo data indicate that c-FLIPL depletion 
inhibits tumor growth through induction of apoptosis and inhibition of 
proliferation, indicating that c-FLIPL plays a key role in ovarian tumor 
progression. Our study highlights c-FLIPL as a central switch between cell 
proliferation and cell death at the DISC level in OC, suggesting that c-FLIPL is 
a potential target for OC therapy. 
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Supplementary data 
 
Supplementary figure 3.2.1. Expression of DR4 in selected OC cell lines. 
Immunoblotting analysis of DR4 and actin expression in MDAH-2774 and A2780 OC 
cell lines. 
 
A) 
 
B) 
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Supplementary figure 3.2.2. c-FLIPL depletion sensitizes OC cells for TRAIL-
induced apoptosis. A) RNAs were isolated from untransfected MDAH-2774 and 
A2780 OC cells and those transfected with a vector encoding control shRNA or c-
FLIP shRNA2. qRT-PCR was performed using specific primers for c-FLIP and 
HPRT1. Columns represent the mean of duplicate of one experiment; bars, ±S.E.M. 
Data represent three independent experiments. B) Parental MDAH-2774 and A2780 
cell lines or those transfected with control shRNA, c-FLIP shRNA1, or c-FLIP 
shRNA2 were either left untreated or treated with soluble TRAIL (100 ng/ml) for 24 
hours. Apoptosis was determined by annexin-V and PI staining. Columns hold the 
mean of three independent experiments: bars, ±S.E.M.; *statically significant 
(P<0.05), or **highly significant (P<0.005) differences obtained by comparing c-FLIP 
shRNA1/2 transfected cells to either parental or control shRNA transfected cells. 
 
A) 
 
B) 
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C) 
 
 
 
Supplementary figure 3.2.3. c-FLIPL depletion causes regression of OC in a 
xenograft mouse model. A) For each experimental group, holding five female 
nude/nude mice, the animals were inoculated subcutaneously with 1.5x107 A2780 
ovarian tumor cells either as parental or transfected with control shRNA1 or c-FLIP 
shRNA1 into left and right ventral flank (day 0). Tumor volumes were measured 
every second day for a period of 14 days. Each measurement in each group 
represents the sum of both left and right tumor volumes per animal and is depicted 
by box plot; the line inside each boxplot indicates the median, and boxes at 25th and 
75th percentiles indicate error bars at minimum and maximum, respectively (results 
are based on two independent experiments). * P<0.05,  ** P<0.005, comparing tumor 
volume in c-FLIP shRNA1 group with either parental or control shRNA groups. Two 
mice in the c-FLIP shRNA1 inoculated group were excluded from the analysis due to 
inoculation resulting in intraperitoneal tumors. B) Correlation between tumor volume 
on day 14 and tumor weight in all mice as found in two independent experiments. C) 
Tumor weight of the given (two independent experiments) as found after 14 days is 
depicted by box plots; *statistically significant (P<0.05), or **highly significant 
(P<0.005) differences comparing the c-FLIP shRNA1 group with parental or control 
shRNA groups. Every weight measurement in each group is represented by the sum 
of both left and right tumor per animal. 
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3.3. Characterization of the TRAIL pathway in a 
syngeneic mouse model of ovarian cancer 
Introduction 
Most human tumors eventually continue to grow independently of 
spontaneous or therapy induced immune responses, a process described as 
escape from tumor surveillance. There is ample evidence that this rests on 
the ability of a fraction of cancer cells to continuously evade potentially 
effective immune recognition and destruction (1-3). Immunosurveillance 
against tumors is mediated by both innate and adaptive components of 
cellular immunity. Endogenous TRAIL protein expressed mainly on a variety 
of cells of innate and adaptive immune cells, and its expression depends on 
the stimulation status (4-10). IFN-γ can induce expression of TRAIL on 
dendritic cells (DCs) and NK cells (4, 5). Increased expression of TRAIL was 
detected on monocytes and macrophages after stimulation with 
lipopolysaccharide (LPS) and interferon-β (11, 12). Moreover, TRAIL is 
upregulated on the surface of CD4+ and CD8+ human T cells after T-cell 
receptor stimulation, in presence of type I IFNs. TRAIL has been shown to 
suppress tumor growth of various types such as B-cell lymphoma (13) and 
breast and renal carcinoma cells (14-16). However, the role of TRAIL-
mediated tumor surveillance in the context of ovarian tumors is unclear. As 
mentioned before, human TRAIL has two known functional receptors DR4 
and DR5 and two additional decoy receptors (cell-bound receptors incapable 
of driving apoptosis signals) DCR1 and DCR2. In addition, human TRAIL can 
bind with OPG (17, 18). By contrast, in mice there is only one death-inducing 
receptor homologous to human DR5 (mTRAIL-R2/mDR5), and two potential 
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decoy receptors (mDcTRAIL-R1 and mDcTRAIL-R2) specific for mouse 
TRAIL (19). Even though, the homology between the human and murine 
TRAIL ligands is only 65%, murine TRAIL has been shown to have some 
cross-reactivity with human tumor cells (20). Mouse DR5 (mDR5) contains the 
death domain and apoptosis can be induced in response to both mouse and 
human TRAIL (21). Interestingly, the overall sequence structures of 
mDcTRAIL-R1 and mDcTRAIL-R2 are distinct from those of the known 
human decoy TRAIL receptors. OPG can also bind to mouse TRAIL, and 
might act as soluble decoy receptor for TRAIL (21). 
Although both subcutaneous and intraperitoneal xenograft OC mouse 
models have provided useful insights into clinical treatment (22-29), 
understanding early events in the establishment and progression of OC is not 
possible in immunodeficient mice. The immunocompetent mouse model I 
applied in this study (30) is based on established models utilizing human and 
rat ovarian surface epithelial cells and tumor cell lines (25, 29, 31-33). Rat 
ovarian surface epithelial cells become transformed after multiple passages in 
vitro and have been shown to develop tumors in athymic mice (32, 33). The 
hypothesis is that multiple passages of ovarian surface epithelial cells might 
cause transformation, which is in line with the theory of incessant ovulation 
and development of OC (32, 34). 
In this part of my PhD thesis I utilized a syngeneic mouse model using 
ten transformed mouse ovarian surface epithelial (MOSE) cell lines derived 
from C57BL/6 mice to assess the implications of TRAIL in OC. I characterized 
all tumorigenic MOSE cell lines in terms of the most relevant players in the 
TRAIL signaling pathway (mDR5, c-FLIP and caspase-8), and measured their 
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sensitivity to TRAIL-induced apoptosis. Interestingly, I observed that all 
tumorigenic MOSE cell lines showed a downregulation of mDR5 when 
compared with normal (non-tumorigenic) MOSE cells. Additionally, seven out 
of ten cell lines were resistant to TRAIL-induced apoptosis. I subsequently 
focused on the well-characterized MOSE ID8 cell line. In vivo preliminary data 
showed that the knockdown of mDR5 by shRNA in the selected ID8 cells 
accelerated the development of ascites compared to control shRNA and 
parental cells. Moreover, the downregulation of mDR5 inhibited significantly 
the apoptosis rate. In vitro data as well as preliminary in vivo results clearly 
suggest that the TRAIL/TRAIL-R2 system plays a fundamental role in tumor 
progression in an accepted immunocompetent OC mouse model. 
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Material and Methods 
Tumorigenic MOSE cell lines 
Tumorigenic MOSE cell lines have been kindly provided by Dr Kathy Roby 
from the University of Kansas, USA. These cell lines were isolated from 
C57BL/6 mice, cultured in vitro, and underwent spontaneous transformation 
after multiple passages. The parental cell line was cloned and ten tumorigenic 
MOSE cell lines were established (Fig. 3.3.1). 
Tumorigenic MOSE cells (greater than pass 20) were subcultured at 1-
2 week intervals in complete medium (DMEM supplemented with 4% FCS 
(Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml insulin, 5 µg/ml 
transferring, and 5 ng/ml sodium selenite (Sigma)) and split at ratios of 1:10. 
 
 
Figure 3.3.1. Schematic map of applying the syngeneic OC mouse model. 
Tumorigenic MOSE cell lines enriched by mouse ovarian surface epithelial cells were 
isolated from C57BL/6 donor mice. Proliferation of MOSE cells was induced by 
adding murine epidermal growth factor (EGF), and cells became transformed after 
multiple passages. The ID8 MOSE cell line was selected and genetically manipulated 
by downregulating mDR5. Parental and manipulated cells were subsequently 
transplanted individually into immunocompetent C57BL/6 recipient mice. Eight weeks 
after tumorigenic MOSE cells reconstitution, the development of OC cells was 
analyzed. 
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Isolation and culturing of normal (non-tumorigenic) ovarian epithelial 
cells 
Ovaries were isolated from five female C57BL/6 mice (eight weeks old; 
Charles River) and placed in a culture dish containing 1xPBS (Gibco) at 4ºC, 
under sterile conditions. The ovaries were washed with 1xPBS and placed in 
a 15 ml conical culture tube containing 10 ml 1xPBS with 0.2% trypsin. The 
ovaries were incubated in a horizontal position in a tube containing trypsin 
solution at 37ºC in a humidified atmosphere of 5% CO2 and air for 30 minutes. 
After 30 minutes, the media containing epithelial cells was transferred to a 
fresh tube and 5 ml complete medium was added. The epithelial cells 
(approximately 100.000 per 10 ovaries) were harvested by centrifugation 
(1000g for 10 minutes at 22ºC), and were resuspended in 2 ml complete 
medium and placed in a single well of a 6-well culture dish (all cells were 
subcultured with trypsin (0.2%) at near confluent). 2 ng/ml murine epidermal 
growth factor (EGF, Sigma) was added to the medium during the early 
passage growth. 
 
RNA isolation, cDNA synthesis, and qRT-PCR 
RNA isolation, cDNA synthesis and qRT-PCR were performed as described in 
sections 3.1 and 3.2. For quantitative real time PCR, the following mouse 
assay-on-Demand probes were used: Mm00457866_m1 DR5, 
Mm01255578_m1 c-FLIP, Mm00437174_m1 TRAIL, and Mm01545399_m1 
HPRT1. 
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Protein preparation and Western blot analysis 
Protein preparation and Western blot were performed as described before in 
sections 3.1 and 3.2. The following primary antibodies were used: monoclonal 
anti-mouse TRAIL-R2 (DR5)/TNFRSF10B antibody (dilution 1:250; R&D 
systems), monoclonal anti-mouse FLIP antibody (Dave-2, dilution 1:1000, 
Alexis), monoclonal anti-mouse caspase-8 antibody (1G12; dilution 1:1000; 
Alexis), and goat polyclonal actin HRP (dilution 1:500; Santa Cruz) antibody. 
The protein bands were quantified using Epi Chemi II Darkroom chamber 
(UVP laboratory products) and LabWork Gel-Pro Application software. 
 
Apoptosis Assay 
Apoptosis assay was performed as decribed before in sections 3.1 and 3.2. 
Briefly, MOSE cell lines were treated with recombinant mouse soluble TRAIL 
(Alexis) at final concentrations of 100, 500 and 1000 ng/ml and incubated for 
24 hours. Cells were harvested by trypsinization and assessed for apoptosis 
by a propidium iodide and annexin-V staining assays according to the 
manufacturer’s instruction. The degree of apoptosis was calculated by 
subtracting measured apoptosis in treated cells from untreated controls. 
 
Generation of RNAi  
Oligonucleotides encoding shRNA targeting mDR5 were designed by using 
Ambion's online Target Finder (Fig. 3.3.2). The specific target sequence for 
mDR5 (accession number: AF176833) are shown in Table 3.3.1. Control 
shRNA was used to confirm the specificity of selected shRNAs. 
Oligonucleotides were annealed by mixing 10 µg of each oligonucleotide 
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(forward and reverse) with 2 µl 10x annealing buffer (1 M NaCl and 100 mM 
Tris HCl ‘pH 7.4’) in a total volume of 20 µ l. The reaction mixture was 
incubated at 95ºC for 5 minutes and then cooled down slowly at room 
temperature. 
The oligonucleotides were designed to contain restriction sites BamHI 
and HindIII at 5' and 3' respectively. 1 µg/µl pSilencer 4.1-CMV neo vector 
(Applied Biosystems) was linearized by digestion with BamH1/HindIII, 
followed by gel purification on a 1% agarose gel. The annealed 
oligonucleotides were cloned into a pSilencer 4.1-CMV neo vector and 
sequences of the resulting vectors were verified by sequencing. 
ID8 MOSE cell line was then transfected with the according vectors 
(encoded shRNA oligonucleotide) by the lipofecatmine transfection method 
(Invitrogen) according to the manufacturer's instructions. To measure the 
suppression level of the mDR5 target gene mRNA and protein were isolated, 
and qRT-PCR and Western blot were performed respectively. 
 
 
 
 
 
 
 
 
 
Figure 3.3.2. Schematic map of the design of the shRNA target sequence. A 
prototypical shRNA is comprised of two hybridized RNA molecules with 19 
complementary nucleotides (derived from mRNA sequence), a loop sequence 
separating the two complementary domains, and 3′ polythymidine tract to terminate 
transcription. Transcription is regulated by the CMV promoter. 
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Target name Oligonucleotide sequence 
 
A Forward: 
5'-GATCC GCGCAGACTTCTATATAGC TTCAAGAGA 
GCTATATAGAAGTCTGCGCTTA-3' 
Reverse: 
5'-AGCTTAAGCGCAGACTTCTATATAGCTCTCTTGAA 
GCTATATAGAAGTCTGCGCG-3' 
B Forward: 
5'-GATCCATACGGTGTGTCGATGCAATTCAAGAGA 
TTGCATCGACACACCGTATTTA-3' 
Reverse: 
5'-AGCTTAAATACGGTGTGTCGATGCAATCTCTTGAA 
TTGCATCGACACACCGTATG-3' 
C Forward: 
5'-GATCCCCGGAAGTGTGTCTCCAAATTCAAGAGA 
TTTGGAGACACACTTCCGGTTA-3' 
Reverse: 
5'-AGCTTAACCGGAAGTGTGTCTCCAAATCTCTTGAA 
TTTGGAGACACACTTCCGGG-3' 
D Forward: 
5'-GATCCAGTGCGAACTCTGTGCATTTTCAAGAGA 
AATGCACAGAGTTCGCACTTTA-3' 
Reverse: 
5'-AGCTTAAAGTGCGAACTCTGTGCATTTCTCTTGAA 
AATGCACAGAGTTCGCACTG-3' 
E Forward: 
5'-GATCCCCTGGCAAGACTCAGAAAATTCAAGAGA 
TTTTCTGAGTCTTGCCAGGTTA-3' 
Reverse: 
5'-AGCTTAACCTGGCAAGACTCAGAAAATCTCTTGAA 
TTTTCTGAGTCTTGCCAGGG-3' 
 
Table 3.3.1. Oligonucleotide sequences of the various hairpins used for the 
knockdown of  mDR5. The sequences of the forward and reverse primers are 
shown. Five oligonucleotides were designed (A, B, C, D, and E). The underlined 
sequences were added for cloning purposes and contain restriction sites (BamHI or 
HindIII) required for cloning. The red sequence indicates the hairpin. 
 
Immunocompetent OC mouse model 
Female immunocompetent C57BL/6 mice, eight weeks of age, were injected 
intraperitoneally with a single-cell suspension (5x106 cells in 0.2 ml DMEM 
containing no additives) of the individual parental or manipulated ID8 MOSE 
cell line. Observation and measurement of the tumor development were 
performed by weighting mice every 2-3 days after inoculation. Intraperitoneal 
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tumor formation was monitored by the accumulation of ascitic fluid. 
Approximately two weeks after the development of visible ascites (detected by 
abdominal swelling) the animals were sacrificed. Ascitic fluid was collected at 
the time of sacrifice and the tumor sizes were noted. As a control, mice were 
injected with DMEM medium free cells to ensure that the observed tumors are 
due to the inoculated tumor cells. Animal experiment was performed 
according to protocols approved by the Austrian Federal Ministry for 
Education, Science and Art 
 
H&E staining and Immunohistochemistry  
H&E staining and Immunohistochemistry were performed as described before 
in sections 3.1 and 3.2. The following primary antibodies were used: 
monoclonal anti-mouse TRAIL-R2 (DR5) antibody (dilution 1:100, R&D 
systems), goat anti-mouse TRAIL antibody (dilution 1:1200, R&D systems), 
and monoclonal rat anti-mouse Ki-67 (dilution 1:25, Dako). 
 
Tunel assay 
Apoptosis was assessed by TUNEL (Roche) according to the manufacturer’s 
instructions. As described before in sections 3.1 and 3.2, cells were analyzed 
on a fluorescence microscope (Nikon Eclipse 800) equipped with a Nikon DS-
R1 camera, using the NIS-Elements software. Positive and negative controls 
were performed by treating samples with DNase I or excluding incubation with 
primary antibody, and yielded positive and negative results, respectively. 
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Statistical analysis 
Data were analyzed using the Student’s t-tests. P values below 0.05 were 
considered as statistically significant, and P values below 0.005 were 
considered highly significant. 
Results and Discussion 
   113 
Results 
Tumorigenic MOSE cell lines regulate differentially mDR5 and c-FLIP, 
and are resistant to TRAIL-induced apoptosis 
Tumorigenic clonal MOSE cell lines (kindly provided by a collaboration 
partner) were derived from the ovarian surface epithelium of C57BL/6 mice 
(30). MOSE cell lines were isolated and cultured in vitro and underwent 
spontaneous transformation after multiple passages. The parental cell line 
was cloned and ten lines were established [(30) and Fig. 3.3.1 in Materials 
and Methods]. 
First, I aimed to characterize the ten tumorigenic MOSE cell lines and 
to examine the status of the TRAIL-dependent apoptosis signaling pathway in 
each of them. I isolated MOSE cells from C57BL/6 mice as outlined in (30) 
and used as normal (non-tumorigenic) MOSE cell control for the endogenous 
expression of the target genes. The expression of the target molecules 
mDR5, c-FLIP and caspase-8 were determined on the mRNA and protein 
level by qRT-PCR and Western blot respectively, and compared to normal 
MOSE cell levels. Unexpectedly, all ten tumorigenic MOSE cell lines 
displayed a downregulation of mDR5 as compared with the non-tumorigenic 
MOSE cell at mRNA and protein level (Fig. 3.3.3A, B and C). By contrast, c-
FLIP showed an upregulation in four out of ten tumorigenic MOSE cell lines 
(IC5, ID3, 2C12 and 3E3) compared with the non-tumorigenic MOSE cells at 
protein level (Fig. 3.3.3B and C upper panel). Expression of caspase-8 was 
unaltered in all ten tumorigenic MOSE cell lines as compared with the non-
tumorigenic MOSE cell control at protein level (Fig. 3.3.3B and C lower 
panel). 
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Furthermore, the sensitivity of the established MOSE cell lines to 
TRAIL were measured by stimulating with soluble mouse recombinant TRAIL, 
and the degree of apoptosis, in a concentration-dependent manner, was 
determined (Fig. 3.3.3D). I incubated the ten cell lines with recombinant 
mouse soluble TRAIL at final concentrations of 100, 500 and 1000 ng/ml for 
24 hours. Apoptosis was then detected by Annexin-V and PI staining and 
compared with untreated controls. Three out of ten tumorigenic MOSE cell 
lines (IC5, ID9, and 3B11) showed response to TRAIL-induced apoptosis only 
at very high concentrations (1 µg/ml, Fig. 3.3.3D). As mentioned above, all ten 
tumorigenic MOSE cell lines downregulated mDR5 but at different levels. The 
expression of mDR5 in all ten tumorigenic MOSE cell lines was positively 
correlated with apoptosis rate. For example, IC5 and 3B11 tumorigenic MOSE 
cell lines showed high apoptosis upon stimulation with TRAIL and expressed 
high mDR5 in comparison with other tumorigenic MOSE cell lines. 
Taken together, these data show that all ten tumorigenic MOSE cell 
lines showed differential expression of the most relevant players in the TRAIL 
pathway (mDR5 and c-FLIP) when compared with normal (non-tumorigenic) 
MOSE cells. I further showed that 70% of tumorigenic MOSE cell lines were 
resistant to TRAIL-induced apoptosis. In conclusion, these results indicate 
that mDR5 and c-FLIP in the context of TRAIL pathway were highly modified 
in mouse OC cells. 
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A) 
 
 
B) 
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C) 
 
 
 
D) 
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Figure 3.3.3. Tumorigenic MOSE cell lines regulate differentially mDR5 and c-
FLIP, and are resistant to TRAIL-induced apoptosis. A) mRNA expression levels 
of mDR5 and c-FLIP in tumorigenic MOSE cell lines were determined by qRT-PCR. 
B) Western blot analysis of mDR5, c-FLIP and caspase-8 expression in ten 
tumorigenic MOSE cell lines. Western blots were performed with the total cellular 
proteins of the given cell lines. C) Quantitative evaluation of Western blot for mDR5, 
c-FLIP (upper panel) and caspase-8 (lower panel). Protein bands were quantified 
and standardized with actin. D) Measured TRAIL sensitivity on tumorigenic MOSE 
cell lines. MOSE cell lines were treated with recombinant mouse soluble TRAIL at 
final concentrations of 100, 500 and 1000 ng/ml and incubated for 24 hours. Cells 
were then assessed for apoptosis by Annexin-V and PI staining and compared with 
untreated controls. No effects were observed with 100 and 500 ng/ml soluble TRAIL 
(data not shown). 
 
Knockdown of mDR5 leads to an increase in transformation and a 
shorter life span 
To analyze the influence of differentially expressed mDR5 on the 
development of OC in immunocompetent mice, the loss of function approach 
was applied using RNAi technology. The well-characterized tumorigenic 
mouse OC cell line ID8 (of which the chromosomes were analyzed and 
structural abnormalities were described (30)), which displays an abnormal 
regulation of mDR5 and c-FLIP (Fig. 3.3.3A, B and C), was selected and 
considered for further work. To shutdown (or at least reduce) mDR5 
expression by RNAi approach, five synthetic shRNA oligonucleotides (A, B, C, 
D, and E; sequence shown in Table 3.3.1 in Material and Methods) spanning 
various regions of the mDR5 open-reading frame were designed and cloned 
into pSilencer 4.1-CMV neo vector. 
The effects of shRNA constructs were controlled by comparing mRNA 
and protein levels from pSilencer mDR5 vector-transfected ID8 cells with non-
transfected ID8 cells or with cells transfected with control shRNA. Control 
shRNA sequence was designed not to target any gene in the whole genome. 
One out of five generated shRNAs showed highly efficient downregulation of 
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mDR5 on mRNA and protein level as shown in qRT-PCR and Western blot 
respectively (Fig. 3.3.4A and B). 
 Consequently, 5 ×  106 of the manipulated and parental tumorigenic 
MOSE cell lines were transplanted intraperitoneally with a single cell 
suspension into female immunocompetent C57BL/6 mice individually, and 
tumor development was determined. Three mice were analyzed per group. 
Mice were weighed every second day, and intraperitoneal tumor formation 
was monitored by the accumulation of ascitic fluid. Approximately 9-18 days 
after the development of visible ascites (detected by abdominal swelling) the 
animals were sacrificed. Interestingly, I observed that suppression of mDR5 
led to an increase in transformation and, consequently, a shortened life span 
(Fig. 3.3.4C). This might be explained by the inhibition of mDR5 expression 
thereby increasing the resistance of ID8 cell lines to TRAIL-induced apoptosis 
expressed by immune cells. I could not observe any tumors outside the 
peritoneal cavity. Notably, these in vivo data were obtained from single 
experiment and, therefore, should be considered preliminary results. My 
preliminary in vivo results indicate that mDR5 is a key player in OC 
progression. 
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A)        B) 
 
 
C) 
 
 
Figure 3.3.4. Knockdown of mDR5 leads to an increase in transformation and 
shorter life span. A and B) Knockdown of mDR5 in the established OC mouse 
model. ID8 tumorigenic MOSE cells were either left untransfected or transfected with 
control shRNA or mDR5 shRNA. RNA and protein were isolated and the efficiency of 
mDR5 shRNA was determined by qRT-PCR (left panel) and Western blot (right 
panel). C) The phenotypic effect of mDR5 suppression on OC progression in a 
syngeneic OC mouse model. Groups of female immunocompetent C57BL/6 mice 
(three mice each), eight weeks of age were either left or transplanted 
intraperitoneally with 5 × 106 ID8 cells of the individual parental or control shRNA or 
mDR5 shRNA MOSE cells. Mice were weighed twice per week after inoculation and 
tumor formation was monitored by the accumulation of ascitic fluid (detected by 
abdominal swelling). 
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Knockdown of mDR5 increases the resistance to TRAIL-induced 
apoptosis in vivo 
To correlate the observed tumor growth with the rate of apoptosis in vivo, 
isolated tumors were subsequently sectioned for pathological analysis. 
Tumors stained with mDR5 confirmed that mDR5 is silenced in vivo compared 
with the control shRNA or parental cells (Fig. 3.3.5A). Immunohistochemical 
analysis for TRAIL indicated that it is highly expressed in the tumor 
microenvironment (Fig. 3.3.5A), which is in line with my previous data from a 
xenograft mouse model (section 3.1). Tumor tissues stained with proliferating 
cell nuclear antigen (Ki-67) showed no significant increase in the proliferation 
in mDR5 downregulated tumors compared with controls (Fig. 3.3.5A and B). 
In contrast, tumor tissues stained via TUNEL assay, which detects 3' DNA 
strand breaks, showed marked decrease in the frequency of apoptosis 
occurring in mDR5 shRNA expressing tumor tissues compared with the 
control shRNA or parental cells (Fig. 3.3.5A and C). Soluble TRAIL induces 
apoptosis in tumor cells and membrane-bound TRAIL is known to be more 
active than soluble TRAIL. Moreover, specific microenvironment plays a role 
in vivo. These facts might explain the reason of reduced apoptosis (only 4%) 
in parental cells in vivo and not in vitro (Fig. 3.3.3D and 3.3.5C). These data 
obtained from preliminary in vivo results suggest that the increase in tumor 
development and shorter life span occurring in mDR5 shRNA expressing cells 
is because of a decrease in apoptosis rate in vivo. Taken together, these 
preliminary in vivo results next to my previous data (section 3.1) highlight DR5 
as a potential target for OC therapy. 
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A) 
 
B)      C) 
 
Figure 3.3.5. Knockdown of mDR5 increases the resistance to TRAIL-induced 
apoptosis in vivo. A) Immunohistochemical analysis of tumor sections isolated from 
the given groups and stained with mDR5, TRAIL or Ki-67. In addition, apoptosis was 
determined by TUNEL assay. B) The percentage of Ki-67 positive cells in each group 
is shown. Columns represent the mean of proportional cell numbers of Ki-67 positive 
staining of three different tumor sections per group; bars, ±SE. No statically 
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significant (P<0.05) difference was obtained by comparing the mDR5 shRNA group 
with parental or control shRNA groups. C) Percentage of TUNEL positive cells is 
shown. Columns represent the mean of the proportional cell numbers of TUNEL 
positive staining of three different tumor sections per group; bars, ±SE; *statically 
significant (P<0.05) or **highly significant  (P<0.005) differences comparing the 
mDR5 shRNA group with parental or control shRNA groups. 
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Discussion 
TRAIL is a natural immune system associated molecule that has been shown 
to play an important role in tumor immunosurveillance, and is in the meantime 
also being developed for clinical trials in cancer patients (15, 16, 35, 36). In 
this study, I applied an immunocompetent C57BL/6 OC mouse model (30) to 
address the molecular and cellular events of the TRAIL/TRAIL-R system in 
host protection from ovarian tumor development. This immunocompetent OC 
mouse model, reflecting both the early and late stages of the disease, is ideal 
for the investigation of the molecular and immune interaction of the TRAIL 
pathway in OC progression. The model has the following benefits. First, the 
ability of tumorigenic MOSE cells to grow in mice with an intact immune 
system, which makes it possible to study the interaction of the immune 
system during the development, progression and treatment of ovarian 
carcinogenesis in contrast to xenograft mouse models, which lack a functional 
immune system. Second, the development of the tumor requires a long time 
(about 2-3 months), which allows for the detection and manipulation of cellular 
and molecular processes during development of the disease. Third, the ability 
to maintain the tumorigenic MOSE cell lines in culture aids genetic 
manipulation. Fourth, the ability of tumorigenic MOSE cells (manipulated and 
parental) to grow in gene deficient mice i.e. TRAIL knock-out C57BL/6 mice, 
makes this model a potential tool for further TRAIL-based studies. 
MOSE cells were isolated and cultured in vitro and underwent 
spontaneous transformation after multiple passages (30). The parental cell 
line was cloned and ten lines were established [(30) and Fig. 3.3.1 in 
Materials and Methods]. Upon intraperitoneal application in a syngeneic 
Results and Discussion 
   124 
C57BL/6 mice, all ten cell lines were capable of inducing intraperitoneal 
tumors, with ascitic fluids accumulating at a late stage of OC, like in women 
(30). In fact, epithelial cells isolated from the surface of mouse ovaries grew 
very slowly. Therefore, to establish these tumorigenic MOSE cells, EGF was 
added to the culture medium to accelerate its growth. In another experiment, 
in the absence of EGF, transformed phenotype was also observed in vitro 
(30). This observation suggested that the transformation of these cells is 
related to the degree of proliferation (30). Remarkably, incessant ovulation is 
a risk factor in OC because it increases the proliferation of the surface 
epithelium (34). Early MOSE cell passages exhibit classical morphology of 
epithelial cells; proliferation was stopped when cells became confluent. 
However, with multiple passages the morphology of cells changed, with the 
contact inhibition of growth mainly lost and cell proliferation continuing. In this 
study, I identified that the TRAIL pathway is altered in malignant cells, which 
might be one of the factors responsible for that transformation. 
Established tumorigenic MOSE cell lines were kindly provided by 
collaboration partner (30). I isolated MOSE cells from C57BL/6 mice and used 
a normal (non-tumorigenic) MOSE cell control for the endogenous expression 
of the target genes. I characterized ten tumorigenic MOSE cell lines in terms 
of their expression of mDR5, c-FLIP and caspase-8, and furthermore 
measured their sensitivity to TRAIL-mediated apoptosis. I observed that 
mDR5 is downregulated in all ten tumorigenic MOSE cell lines when 
compared with normal (non-tumorigenic MOSE cells) (Fig. 3.3.3A, B, and C). 
Moreover, I documented that 70% of tumorigenic MOSE cell lines are 
resistant to TRAIL-induced apoptosis, and 30% showed apoptosis upon 
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treatment with mouse soluble TRAIL. These cells showing a response to 
TRAIL-induced apoptosis expressed higher levels of mDR5 compared with 
those resistant to TRAIL-induced apoptosis (Fig. 3.3.3). These data suggest 
that the sensitivity of tumorigenic MOSE cell lines to TRAIL-induced apoptosis 
is directly correlated with mDR5 expression. My observation in mice is in line 
with my previous finding in humans that resistance to TRAIL in OC can be 
overcome by an agonistic anti-human DR5 monoclonal antibody, such as 
AD5-10, together with an application of TRAIL (section 3.1). c-FLIP 
expression was altered in 40% of the tumorigenic MOSE cell lines at protein 
level when compared with non-tumorigenic MOSE cell control (Fig. 3.3.3B 
and C). This finding reflects our lab’s observation in humans that about 40% 
of OC patients overexpressed c-FLIPL, and that c-FLIPL suppression 
enhanced OC to TRAIL-induced apoptosis (22, 37). Taken together, these 
data indicate that the immunocompetent OC mouse model I applied in this 
study closely mimics human disease, proving valuable in current 
investigations. 
The immunocompetent OC mouse model develops widespread 
intraperitoneal disease with morphological characteristics of epithelial OC 
within two to three months after injection. No metastatic disease could be 
observed in these mice, and this fact is verified in my study. Notably, human 
OC metastasizes into the free peritoneal cavity and is restricted to the 
peritoneal cavity. Metastases at other sites are a rare event. The well-
characterized tumorigenic mouse OC cell line ID8 was genetically 
manipulated by inhibiting mDR5 expression using shRNA (Fig. 3.3.4A and B). 
Interestingly, the preliminary data of a syngeneic OC model showed that 
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silencing mDR5 expression decreased the life span of OC mice. Moreover, 
ascite development was accelerated and apoptosis was decreased in tumor 
tissues downregulated mDR5 compared with control shRNA or parental cells 
(Fig. 3.3.4C, 3.3.5A and B). These results indicate that mDR5 contributes 
significantly to TRAIL-induced apoptosis in OC cells and support my previous 
findings in humans that AD5-10 sensitized OC cells to TRAIL mediate 
apoptosis in vitro and decreased dramatically tumor size in vivo (section 3.1). 
In conclusion, my data show that the TRAIL/TRAIL-R system in 
addition to the caspase-8 inhibitor protein c-FLIP is modified in mouse OC, 
and that the alterations are very similar to that observed in human OC. This 
fact indicates the value of my study, and adds additional weight for applying 
syngeneic OC models to the study of the TRAIL pathway in an 
immunocompetent setting. Moreover, immunotherapeutic strategies designed 
to treat OC will be evaluated using this model in future experiments. 
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Future Directions 
In the future experiments, we will explore the role of TRAIL in natural 
antimetastatic function of immunosurveillance against ovarian transformed 
cells in vivo, using TRAIL knock-out mice (will be kindly provided by 
collaboration partner). We will analyze the inhibitory effect of TRAIL on the 
outgrowth of OC by reconstituting TRAIL deficient C57BL/6 mice with parental 
or manipulated tumorigenic MOSE cell lines and detect the metastatic spread 
of the tumor cells.  
Next, in order to demonstrate the contribution of TRAIL in NK cell 
surveillance of OC; first, we will assess the primary growth of tumorigenic 
MOSE cells transplanted into pathogen-free C57BL/6 and TRAIL knock-out 
mice (having the same genetic background). Second, pathogen-free C57BL/6 
mice reconstituted with tumorigenic MOSE cells will be treated with IL-12 and 
either depleted from NK cells or treated with anti-TRAIL mAb. Notably, IL-12 
has been shown to induce proliferation, IFN-production and cytotoxicity of NK 
cells in vivo, which is associated with their antitumor effects (38-40). 
Subsequently, the antitumor effect will be detected and compared to TRAIL 
knock-out mice reconstituted with the same tumorigenic MOSE cells. This 
experiment will illustrate the critical role of TRAIL expressed on NK cell in 
mediating antitumor activity against OC. 
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4. Conclusions 
The main focus of my PhD work was to demonstrate the key role of the most 
relevant player in TRAIL signaling pathway, namely the TRAIL functional 
receptor 2 (DR5) and c-FLIPL, in suppressing tumor initiation of OC. TRAIL 
has been shown to be one of the most promising agents in selectively 
inducing apoptosis in tumor cells. However, many cancer cells including OC 
are inherently resistant to TRAIL-induced apoptosis, presumably as a result of 
multiple genetic alterations in the TRAIL signaling pathway. Several 
mechanisms underlying TRAIL resistance have been suggested, including 
mutation in DR5 and/or anti-apoptotic protein c-FLIPL. 
 During the course of my PhD thesis, I identified the role of DR5 as well 
as c-FLIPL in OC development. In a study using primary tumor material, I 
selected three different human OC cell lines, namely MDAH-2774, A2780 and 
ES-2. Selected OC cell lines harbored different mutations, ranging from silent 
DR4 expression, upregulation of the inhibitor protein c-FLIPL, and further to 
mutated p53, representing the majority of OC patients. Moreover, these cell 
lines are resistant to carboplatin and recombinant soluble human TRAIL. I 
succeeded to show that stimulation of OC cells with an agonistic antibody 
(AD5-10) against human DR5 in presence of carboplatin restored sensitivity of 
platin-resistance OC cells to apoptosis in vitro and in vivo. Moreover, I could 
show that carboplatin forced expression of DR5 on OC cells independent of 
the p53 status, which might explain the high apoptosis rate observed after 
treating OC cells with a combination of AD5-10 and carboplatin. Furthermore, 
I described that NK cells play a critical role in immunosurveillance and in the 
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function of the agonistic antibody AD5-10 in OC. I reported that depletion of 
mice from NK cells led to increased tumor development and abolished the 
cytotoxic effect of AD5-10 in xenograft mouse model. 
 As second part in my PhD thesis, I aimed to clarify the antagonistic role 
of c-FLIPL in OC progression. I found that c-FLIPL downregulation enhanced 
significantly OC cells to TRAIL-induced apoptosis in both in vitro and 
decreased tumor growth rate in vivo. Moreover, c-FLIPL underexpression 
inhibited migration of OC cells in presence of soluble TRAIL in vitro, and 
hindered invasion of ovarian tumors in a preclinical OC mouse model. 
Interestingly, c-FLIPL suppression inhibits proliferation of OC cells in vivo, 
which might be in line with previous findings that c-FLIPL activates ERK and 
NF-κB -mediated cell proliferation. This finding adds additional weight in the 
role of c-FLIPL in mediating OC development. The summary of this study was 
that c-FLIPL is a fundamental player in controlling the balance between 
proliferation and apoptosis in human OC cells. 
 The results provided in this study, and also complemented by other 
studies showed that TRAIL and DR5 play an essential role in 
immunosurveillance, it was important to further investigate this finding in an 
appropriate animal model. Therefore, in the last part of my PhD thesis, I 
applied an immunocompetent OC mouse model to study TRAIL and DR5 in 
the interplay between cancer cells, microenvironment, and immune system. 
An established immunocompetent OC mouse model showed close 
resemblance to human OC in context of the TRAIL pathway. Accordingly, I 
found that mouse DR5 is an important player in OC progression, since 
silencing mouse DR5 increased ascites development and decreased life span 
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of a syngenic OC mouse in a preliminary animal experiment. Indeed, this 
observation is in line with my previous finding on the key role of DR5 in OC 
development. 
  Collectively, my PhD study provided a unique strategy to illustrate the 
basic framework for the natural TRAIL effector molecule in host protection 
against ovarian tumorigenesis. These results might add new insight into 
several additional aspects of this disease, furthermore supporting novel 
therapy options. 
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